Abstract
Organising pneumonia is defined histopathologically by intra-alveolar buds of granulation tissue, consisting of intermixed myofibroblasts and connective tissue. Although nonspecific, this histopathological pattern, together with characteristic clinical and imaging features, defines cryptogenic organising pneumonia when no cause or peculiar underlying context is found. Rapid clinical and imaging improvement is obtained with corticosteroid treatment, but relapses are common after stopping treatment.
Although previous partial descriptions can be traced back to the latter half of the nineteenth century, as in the lectures given in 1877–1878 by J.M. Charcot in Paris, France 1, the concept of organising pneumonia (a term describing a histopathological pattern) emerged under various names at the beginning of the 20th century 2–9 (fig. 1⇓). For example, Milne 5 described a type of pneumonia “where the usual process of resolution has failed and organisation of the inflammatory exudate in the air alveoli of the lung by fibrous tissue has resulted” (resolution was the third stage in the course of pneumonia as described by Laennec, which followed the stages of congestion and hepatisation). These early observations were mostly made during the autopsy of patients who died due to nonresolving pneumococcal pneumonia before the era of antibiotherapy. These histopathological descriptions of organising pneumonia stated that the initial intra-alveolar material consisted of fibrin, further colonised by fibroblasts and replaced by “fibrillated connective tissue” 6. Intra-alveolar buds of granulation tissue consisting of intermixed myofibroblasts, fibroblasts, and connective matrix, especially consisting of collagens are the hallmark of organising pneumonia.
Organising pneumonia has long been described in the context of pulmonary infection; for several decades, it was often considered as a nonsignificant histopathological witness of a precedent unrecognised infection. Nevertheless, sporadic studies indicated a continuing interest in this entity 10–14. However, it eventually gained a more primordial status when it was correlated in the 1980s with specific clinico-radiological manifestations without any evident cause 15–19. Cryptogenic organising pneumonia (COP), also called idiopathic bronchiolitis obliterans with organising pneumonia (BOOP) rapidly became, despite its relative rarity, a common disorder that was especially gratifying for the clinician due to its prompt improvement under corticosteroid treatment.
PATHOGENESIS
The most intriguing characteristic of intra-alveolar fibrosis, resulting from organisation of inflammatory exudates, is its usual dramatic reversibility with corticosteroids. Although the intra-alveolar buds in organising pneumonia share some morphological features with the fibroblastic foci present in usual interstitial pneumonia (UIP), in contrast to the latter they are not associated with progressive irreversible fibrosis. Therefore, intra-alveolar fibrosis of organising pneumonia represents a unique model of inflammatory lung disease 20, 21, offering many similarities with the process of cutaneous wound healing 22.
The morphological sequential evolution of intra-alveolar fibrosis in human organising pneumonia has been established previously 23–26 (fig. 2⇓). Alveolar epithelial injury is the first event, with necrosis and sloughing of pneumocytes resulting in the denudation of the epithelial basal laminae. Most basal laminae are not destroyed, although some gaps are present. The endothelial cells are only mildly damaged. In contrast with diffuse alveolar damage, no hyaline membranes are found. Inflammatory cells (lymphocytes, neutrophils, some eosinophils) infiltrate the alveolar interstitium. Fibroblasts present in the interstitium exhibit features of activation, such as conspicuous rough endoplasmic reticulum and Golgi apparatus, but these are not increased in number and there are no associated collagen deposits.
The first intra-alveolar stage in the process of organisation is characterised by the formation of fibrinoid inflammatory cell clusters. These comprise prominent bands of fibrin together with inflammatory cells (especially lymphocytes, with some polymorphonuclears, and occasional plasma cells and mast cells). Macrophages engulfing fibrin may be seen.
The second stage is characterised by the formation of fibro-inflammatory buds. Fibrin is fragmented and inflammatory cells are present but less numerous. Fibroblasts migrating from the interstitium through gaps in the basal laminae colonise the fibrin remnants and proliferate, as demonstrated by the presence of mitotic figures. Fibroblasts undergo further phenotypic modulation, especially with the development of intracellular filaments (myofibroblasts). A reticulin framework takes place in the extracellular environment. A proliferation of alveolar cells progressively provides re-epithelialisation of the basal laminae, a crucial phenomenon for the preservation of the structural integrity of the alveolar unit.
The third and final stage of the process of organisation is defined by the characteristic “mature” fibrotic buds. Inflammatory cells have almost completely disappeared in most buds (although some may persist in the centre of some buds), and there is no longer any fibrin within the alveolar lumen. Concentric rings of fibroblasts alternate with layers of connective tissue (mainly collagen bundles). The fibroblasts are typical myofibroblasts with conspicuous filaments in their cytoplasm oriented along the axis of the cells, with an abundant endoplasmic reticulum.
The matrix pattern of the intra-alveolar buds is initially characterised by fibrillar material consisting of fibronectin, type III collagen and proteoglycans, among which the typical periodic (type I) collagen fibres represent a minority, leaving large empty areas of the extracellular space. The cellular rings of fibroblasts–myofibroblasts are then intercalated with connective matrix sheets, consisting of loose bundles of thin collagen type I fibres mixed with fibronectin, collagen and procollagen type III and proteoglycans. In the mature fibrotic buds, the connective network consists of thin collagen I fibres held together by thinner fibrils of collagen and procollagen type III, and fibrin to form bundles resulting in a loose connective network where fibronectin, type III procollagen and collagen are codistributed at a higher rate than type I collagen. This contrasts with the predominant deposition of type I collagen in UIP. A loose connective matrix with high type III collagen content is more susceptible to degradation and reversal of fibrosis 24, 27, 28. Glycoproteins, especially tenascin, are likely to play a role in loosening the adhesive interactions between cells and the pericellular matrix components in COP 29. Collagen VI, coexpressed with collagen III rather than collagen I, may also participate in the regulation of matrix deposition in COP 30.
A further characteristic of the intra-alveolar buds in COP is the prominent capillarisation, which is reminiscent of granulation tissue in wound healing, another type of a reversible fibro-inflammatory lesion 31. Vascular endothelial growth factor and basic fibroblast growth factor are widely expressed in intra-alveolar buds 32. Angiogenesis mediated by these growth factors could contribute to the reversal of buds in organising pneumonia.
Experimental models provide further information about the morphogenesis of intra-alveolar fibrosis. Paraquat in monkeys 33 or lobar instillation of CdCl2 in rats 34 results in intra-alveolar migration of interstitial cells through gaps in the epithelial basement membranes after lung injury. The early damage to type I pneumocytes progressing to necrosis, leaving areas of denuded alveolar membrane with abnormal alveolar repair, is associated with failure of resolution in experimental streptococcal pneumonia in rats 35. In intra-alveolar fibrosis produced by bleomycin in rats, alveolar structural remodelling is seen only when mural incorporation of intra-alveolar buds occurs 36.
An animal model of intraluminal fibrosis has been developed with intranasal inoculation of reovirus serotype 1 into CBA/J mice at a titre of 106 plaque-forming units (pfu) 37. In this model, severe pneumonia, characterised by a prominent peribronchiolar lymphocytic inflammation, further evolves with the formation of intraluminal fibroblastic lesions indistinguishable from organising pneumonia. Interestingly, these lesions develop in CBA/J, but not in other strains of mice, suggesting that genetic host factors are critical in the development of intra-alveolar fibrosis. A model of diffuse alveolar damage with typical hyaline membranes and high mortality has been obtained with the same animal model but using a higher titre (107 pfu) of reovirus 1 38, 39. Thus, the degree of severity of the initial injury seems to be a critical determinant in the progression towards either organising pneumonia or diffuse alveolar damage 38. Furthermore, whereas corticosteroids can both inhibit the development of fibrotic lesions and enhance the resolution of fibrotic lesions in the model of intraluminal fibrosis, in the diffuse alveolar damage model corticosteroids fail to modulate the development of the lesions at any stage 39. The role of T-cells has been explored in the reovirus 1-induced lung injury model, with neonatal thymectomy in mice demonstrating that T-cells are required for the development of organising pneumonia, but not for that of diffuse alveolar damage 40.
The pathohistophysiology recognised by the previous morphological studies in human and animal models offers some cornerstones for the understanding of the biopathology of intra-alveolar fibrosis. The pathogenesis of pulmonary fibrosis involves a complex network and interaction of cells 41–43, mediators 44–48 and extracellular matrix (ECM) components 49–52.
Some other limited information has been published on biopathological features in organising pneumonia. Platelet-derived growth factor 53 and interleukin (IL)-8 54 produced by macrophages are likely to play a role in the pathogenesis of intra-alveolar fibrosis in COP. Pulmonary tissue from rheumatoid arthritis patients with organising pneumonia contains many cells positive for S-100 protein 55. B7-2 and class II major histocompatibility complex molecule expression in alveolar macrophages of patients with organising pneumonia is decreased compared with control subjects 56. The soluble form of the Fas ligand (implicated in the system of apoptosis-signalling receptor molecules) is elevated in the bronchoalveolar lavage (BAL) fluid of patients with COP, which may abrogate the cytotoxicity of the Fas-ligand 57.
Mast cells and released tryptase are increased in the BAL fluid of patients with COP 58. The cytokine profile of BAL in COP is characterised by increased monocyte chemotactic protein-1, IL-10, IL-12 and IL-18 levels with respect to controls and UIP, consistent with a marked degree of macrophage and lymphocyte activation with an expansion of T-helper type-1 response in COP 59.
Some insights into the pathogenesis of organising pneumonia may further be extrapolated with acceptable likelihood from studies in the other infiltrative and fibrosing lung diseases, especially acute respiratory distress syndrome (ARDS; which is characterised by two successive stages of diffuse alveolar damage, namely acute exudative and chronic organising) 20, 21, 60, 61 and idiopathic pulmonary fibrosis (IPF) 62.
Clearly, epithelial alveolar damage with leakage of plasma proteins and further fibrin formation within the alveolar lumen is a crucial initial event, which has been especially studied in ARDS and further emphasised in pulmonary fibrosis 20, 21, 63–68. The formation of fibrin results from an imbalance in the alveolar lumen between the coagulation and fibrinolytic cascades, with a net result of clotting 69. Recently, increased levels of a potent inhibitor of fibrinolysis, thrombin activable fibrinolysis inhibitor, and of protein C inhibitor have been found in the BAL from patients with interstitial lung disease, especially COP 70. In addition to providing a provisional fibrin matrix for the migration of cells (including fibroblasts), the coagulation and fibrinolysis factors and inhibitors (especially plasminogen activator inhibitor-1) play a complex role in fibrogenesis 68. Interestingly, an animal model demonstrated prevention of bleomycin-induced lung fibrosis by aerosolisation of heparin or urokinase 71.
The matrix metalloproteinases (MMPs) that cleave protein components of the ECM play a central role in tissue remodelling 72. Two collagenolytic metalloproteinases are involved in the destruction of subepithelial basement membranes, MMP-2 (preferentially secreted by fibroblasts and epithelial cells) and MMP-9 (preferentially produced by inflammatory cells). In organising pneumonia, MMP-2 is expressed in BAL fluid and by regenerated type II cells, in contrast with UIP where MMP-9 is preferentially expressed 73. In another study, the concentration of MMP-9 and tissue inhibitors of metalloproteinases (TIMP) was increased more in the BAL fluid of patients with COP compared with UIP 74. Although these studies are somewhat contradictory, they suggest that an imbalance between MMP and TIMP may play a role in the remodelling of connective tissue in COP. Interestingly, laminin-5 (a glycoprotein involved in cell attachment, migration, proliferation, differentiation and apoptosis), expressed in epithelial cells of wound healing, is also expressed in regenerating epithelial cells in COP, as well as in UIP 75. However, re-epithelialisation is disturbed in UIP, which may contribute to the progression of fibrosis.
The role of the myofibroblast in wound healing and fibrosis is critical 76, 77. The origin of fibroblasts–myofibroblasts involved in organising pneumonia is not known. Several recent papers have demonstrated that myofibroblasts involved in pulmonary fibrosis in animal models (fibrosis induced by bleomycin or irradiation) are of bone marrow origin and not derived from resident fibroblasts in the pulmonary interstitium 78–80. Whether intra-alveolar myofibroblasts in organising pneumonia could also originate from bone marrow and not from resident interstitial cells is presently unknown. Furthermore, epithelial to mesenchymal transition has been recently emphasised 81.
The disappearance of myofibroblasts and fibroblasts in fibrosis may occur by apoptosis, possibly through loss of transforming growth factor-β signalling 82, 83. Apoptotic activity is increased in the newly formed connective tissue in organising pneumonia 84.
Although several rather similar factors of matrix remodelling are present in both COP and UIP, the reasons for the opposing mechanisms of reversibility of fibrosis in COP and ongoing fibrosis in UIP are not yet established.
A DISTINCT ENTITY AMONG THE IDIOPATHIC INTERSTITIAL PNEUMONIAS
Although the pulmonary lesions in COP are mainly intra-alveolar, COP was included in the American Thoracic Society/European Respiratory Society International Consensus Classification of the Idiopathic Interstitial Pneumonias 85, particularly due to: 1) its idiopathic nature; 2) the possible confusion with other forms of idiopathic interstitial pneumonias (table 1⇓), especially when the imaging pattern is infiltrative; and 3) histopathological features of interstitial inflammation in the involved areas. The previous terminology of BOOP was abandoned because the major process is organising pneumonia, with bronchiolitis obliterans being only a minor and accessory finding (which may even be absent).
Clinical features
For more information regarding the clinical features of COP please refer to 15–19, 86–101. Males and females are equally affected by COP, with mean age of onset ∼50–60 yrs. A few rare cases have been reported in children 102. Nonsmokers or ex-smokers are affected approximately twice as often as smokers, but the proportion of nonsmokers may be higher among females 89, a finding which needs to be confronted with the prevalence of smoking in the different countries. However, COP is clearly a disorder not related to smoking. A seasonal (early spring) occurrence of COP with relapse every year at the same period has been reported 103. Recurrent catamenial COP has also been mentioned 104.
Clinical manifestations begin with a mild flu-like illness with fever, cough, malaise and progressively mild dyspnoea, anorexia and weight loss. Dyspnoea may occasionally be severe, especially in the eventuality of rapidly progressive disease. Haemoptysis is uncommon and seldom severe 105. Other uncommon manifestations include chest pain, night sweats and mild arthralgia (when arthralgia is prominent and/or associated with myalgia an underlying connective tissue disease should be suspected). Air leak (pneumothorax, pneumomediastinum) may be a rare presenting feature 106, 107. Since the most common manifestations are nonspecific, diagnosis is often delayed (6–13 weeks). Physical examination usually discloses focal sparse crackles, but may be almost normal. There is no finger clubbing.
Imaging features
For more information about the imaging features of COP refer to 15–18, 90, 95, 96, 98, 100, 108–133. The three main characteristic imaging patterns of COP consist of multiple alveolar opacities (typical COP), solitary opacity (focal COP), and infiltrative opacities (infiltrative COP) 17. In a study of diagnostic accuracy of thin-section computed tomography (CT) in a series of patients with idiopathic interstitial pneumonias, the correct diagnosis of COP was the highest, in 79% of cases 134, suggesting that the CT imaging features are characteristic.
Typical COP
Multiple alveolar opacities on imaging represent the most frequent and typical imaging features of COP (figures 3⇓ and 4⇓). These are usually bilateral and peripheral, and are often migratory. Their size varies from a few centimetres to a whole lobe, and an air bronchogram is often present in consolidated opacities. On a high-resolution computed tomography (HRCT) scan, the density of opacities ranges from ground glass to consolidation and more opacities are detected than on chest radiographs. This imaging pattern narrows the differential diagnosis, which mainly comprises the idiopathic chronic eosinophilic pneumonias, low-grade pulmonary lymphomas, and bronchioloalveolar lung carcinoma. Idiopathic chronic eosinophilic pneumonia is often associated with asthma and increased blood eosinophil level is present. However, it may overlap with COP, as in the figures of histopathological features reported in the series by Carrington et al. 135, where typical buds of granulation tissue in addition to eosinophilic pneumonia are seen. Other cases of overlap of organising pneumonia and chronic eosinophilic pneumonia (idiopathic or not) have been reported 136–140. Furthermore, increased level of eosinophils in BAL may be found in some patients with COP. In both disorders, relapses are common. The primary pulmonary lymphomas of low grade are also relatively responsive to corticosteroids (but not as rapidly as in COP). In bronchioloalveolar carcinoma, associated nodules are common and there is no regression with corticosteroids.
The typical imaging features of COP are usually so characteristic that they allow the possibility of diagnosis for most experienced clinicians.
Solitary focal opacity
This pattern is not characteristic and the diagnosis of COP is often made from histopathology of a nodule or a mass excised on suspicion of bronchogenic carcinoma 141 (fig. 5⇓). However, organising pneumonia is distinct from round pneumonia improving with antibiotics 142–144. Neutrophilic inflammation or microabscesses may be associated with the typical features of organising pneumonia 145, 146. The lesions are often located in the upper lobes, and may be cavitary. The clinical presentation may be that of COP as described above, but focal organising pneumonia may be totally asymptomatic and discovered by routine chest radiographs (some patients may recall that they had a previous history of pneumonia) 17, 90, 145. The suspicion of carcinoma may be increased by false-positive fluorodeoxyglucose positron emission uptake 147, 148. Solitary focal organising pneumonia usually does not relapse after surgical excision. Possible spontaneous regression of solitary nodular organising pneumonia has been reported previously 149.
Infiltrative COP
Infiltrative COP is often associated with interstitial and superimposed small alveolar opacities on imaging (fig. 6⇓). Some cases overlap with other types of idiopathic interstitial pneumonias, especially IPF and nonspecific interstitial pneumonia (NSIP). In the latter, focal areas of organising pneumonia are often encountered at histopathology 150, 151. However, these are scattered foci, which are small and compose <10% of lesions, with interstitial pneumonia being the main lesion, whereas in organising pneumonia interstitial inflammation does not extend beyond the area of intra-alveolar fibrosis. The infiltrative pattern may consist of a poorly defined arcade-like or polygonal appearance defining a perilobular pattern 152, which is often associated with other opacities, especially consolidation.
Other imaging features
Several other imaging features have been reported 108. The nodular pattern may consist of a well-defined “acinar” pattern with nodules of ∼8 mm in diameter, or of a more subtle poorly defined (micro)nodular pattern. Multiple nodules of organising pneumonia may suggest metastatic lesions 153, especially in patients with a history of cancer. Some reported cases of cavitary COP correspond to consolidation superimposed on emphysema 154. The bronchocentric pattern of COP is defined by areas of consolidation surrounding the bronchovascular bundles. The linear and band-like pattern consists of opacities extending radially to the pleura; some band-like opacities lie in the periphery of the lung parallel to the chest wall (the latter may be observed especially during the resolution of peripheral alveolar opacities). The halo sign 155, or particularly a reversed halo sign, of lung opacities have been reported 156. Other imaging features consist of multiple masses or nodules (possibly excavated), and pneumatocele 132. A diffuse micronodular pattern with histopathological features of bronchiolitis with peribronchiolar organising pneumonia has been reported 157. Pleural effusion is seldom seen in COP, although it was present in 22% of cases in a previous series 90.
Lung function tests
For more information about lung function tests in COP refer to 15–19, 95, 96, 98, 103, 114, 158, 159. A mild or moderate restrictive ventilatory defect is the most common abnormality at spirometry. Airflow obstruction may be present in patients with a history of smoking and underlying chronic obstructive pulmonary disease. The transfer factor of the lung for carbon monoxide is reduced in proportion to restriction, but the transfer coefficient is usually normal. Hypoxaemia at rest and/or during exercise is usually mild. More severe hypoxaemia may be present in patients with widespread lung lesions and rapidly progressive disease. However, some patients have marked hypoxaemia (usually well tolerated) with possible orthodeoxia because of alveolar right to left shunting, as demonstrated by increased alveolar–arterial oxygen difference on breathing 100% oxygen and negative contrast echocardiography 160, 161. This is likely to result from defective vasoconstriction in areas of nonventilated alveoli because of intra-alveolar buds occupying the entire lumen of alveoli.
Biological features
BAL is indicated in all cases where COP is suspected. First, it helps in excluding other diagnoses or determining a cause of organising pneumonia. Thus, it may disclose active infection or neoplastic disorders especially lymphoma and bronchioloalveolar carcinoma (immunocytological analysis may establish the monotype of lymphocytes characteristic of lymphoma). In COP, a mixed pattern at differential cell count may orientate towards the diagnosis. It consists of an increase in lymphocytes (20–40%), neutrophils (∼10%) and eosinophils (∼5%) with the level of lymphocytes higher than that of eosinophils 17, 94, 97, 110, 162–164. A markedly elevated percentage of eosinophils (>25%) may suggest an overlap with idiopathic chronic eosinophilic pneumonia 18, 96, 99, 109, 138. The finding of a few plasma cells and/or mast cells is remarkable in COP. The lymphocytes are activated and the CD4/CD8 ratio is usually decreased 162, 165, 166.
Blood tests do not make a significant contribution to the diagnosis of COP. A moderate leukocytosis is usual with an increase in neutrophils. There is no eosinophilia and the C-reactive protein level and erythrocyte sedimentation rate are increased.
Diagnosis of COP
The diagnosis of COP requires the establishment of a diagnosis of organising pneumonia, then the exclusion of any possible cause (which may be relatively evident or require more laborious aetiological inquiry).
Histopathological diagnosis of organising pneumonia
Histopathological diagnosis of organising pneumonia has been discussed previously elsewhere 167, 168. Once a diagnosis of COP is suspected, obtaining lung tissue for histopathological study is necessary. The hallmark of organising pneumonia is the presence of buds of granulation tissue consisting of fibroblasts–myofibroblasts embedded in connective tissue (fig. 7⇓). These may extend from one alveolus to the next through the interalveolar pores as described in a case of “fibrinous pneumonia” by Kohn 169, thus giving a characteristic “butterfly pattern”. These buds often extend into the bronchioles and may obstruct the lumen (bronchiolitis obliterans of the proliferative type). Mild interstitial inflammation is present in areas of organising pneumonia, and foamy alveolar macrophages are present in those alveoli that are not filled by buds. It must be emphasised that the mere presence of some buds is not sufficient to make a diagnosis of organising pneumonia as the organisation of intra-alveolar exudates is a nonspecific process that may occur in a variety of inflammatory lung diseases 170. This is why pathologists must search carefully for other lesions that could represent the main inflammatory process associated with foci of intra-alveolar fibrosis.
As mentioned previously, the histopathological pattern of NSIP (idiopathic or not) may comprise buds, as may that of Wegener’s granulomatosis, where organising pneumonia is present in 54% 171 to 70% 172 of cases, with organising pneumonia being the main histological finding in some patients 173. They may also be present in eosinophilic pneumonia, hypersensitivity pneumonitis 170, 174, pneumonia distal to obstruction (especially of neoplastic origin), abscesses, aspiration pneumonia 16, 175, 176, cystic fibrosis 177, 178, organising diffuse alveolar damage of any cause, pneumoconiosis 179, or in the vicinity of pleural plaques 180. Furthermore, microbiological studies on lung tissue may be helpful, including special stains to exclude infection, especially opportunistic infection. It is clear that such a meticulous analysis requires a rather large piece of lung tissue.
Video-assisted thoracoscopy (VAT) allows biopsy of the lung in good conditions of security and allows pieces of tissue of sufficient size to be obtained from several lobes (especially when all lesions do not appear of the same type on HRCT) to exclude associated conditions or different patterns of interstitial pneumonia. Currently, VAT is a safe procedure that may be used in most patients.
However, before proposing VAT, transbronchial biopsies are recommended, since the finding of characteristic intra-alveolar buds at histopathological examination is sufficient in most cases to make a provisional diagnosis of organising pneumonia 181, 182, thus allowing treatment in patients with typical imaging features and presumed good compliance for follow-up (hence allowing reconsideration of the diagnosis in the eventuality of unfavourable or atypical evolution under corticosteroid treatment). However, it must be remembered that the amount of lung tissue is relatively small and that the collapse and pinch artefacts induced by the forceps do not usually allow exclusion of other histopathological processes coexisting with foci of organising pneumonia. Therefore, atypical cases of COP diagnosed only on the basis of transbronchial biopsies need to be interpreted with caution, especially when imaging features are more suggestive of NSIP or IPF.
Whether a diagnosis of organising pneumonia may be accepted or not without histopathology and based only on clinical and imaging findings requires consideration, especially because it is increasingly frequent in clinical practice 86. In patients too frail and/or too old to undergo lung biopsy, or refusing lung biopsy, corticosteroid treatment can be started provided patients have been informed that diagnosis is only probable and that a careful follow-up is programmed. Often rapid clinical and imaging improvement reinforces the probability of organising pneumonia. However, since long-term corticosteroid treatment often results in significant side-effects, some patients treated without histopathological confirmation sometimes question the diagnosis, eventually leading to later biopsy, especially on relapse.
Aetiological diagnosis: cryptogenic or not?
Organising pneumonia may be considered cryptogenic, a term used synonymously to idiopathic, although etymologically cryptogenic means of hidden cause and idiopathic means a self-governing disease; the disorder described is both cryptogenic and idiopathic. It is only considered to be cryptogenic when a definite cause or characteristic associated context is not present. Therefore, the aetiological diagnosis is of major importance before accepting the diagnosis of COP.
In non-COP, although some cases present with imaging and histopathological features quite similar to COP, other cases are more atypical especially as associated to histopathological features with more interstitial inflammation and/or fibrosis, and diffuse alveolar damage.
AETIOLOGY OF ORGANISING PNEUMONIA
The aetiological diagnosis of organising pneumonia attempts to establish a determined cause (as a single infectious agent), or a specific context known to be occasionally associated with organising pneumonia, such as connective tissue disease. Several possible causes and/or remarkable contexts may be associated. The clinical and imaging features of “secondary” organising pneumonia are similar to those of COP 90.
Determined causes of organising pneumonia
There are many determined causes of organising pneumonia. In addition to pneumococcal pneumonia, several other infectious agents (including bacteria, viruses, parasites and fungi) have been reported to cause organising pneumonia resulting from nonresolving pneumonia (table 2⇓). Organising pneumonia, which improved with corticosteroids, was reported in a pregnant patient with HIV infection treated with lamivudine and zidovudine 205. In clinical practice, the search for infection is not always exhaustive (sometimes because laboratory diagnostic tools such as serological tests or antigenuria are not available in all infectious disorders). Furthermore, some infections may initiate an uncontrolled inflammatory organising pneumonia process that persists after the aetiological agent has disappeared. An infectious agent may also induce a secondary noxious immunopathological process; a convincing example is rheumatic pneumonia 224, 225 where, in addition to the well known cardiac complications, typical organising pneumonia has been described 225–227, especially by Masson et al. 227, who called the intra-alveolar buds “bourgeons conjonctifs” (connective tissue buds), terminology still used by some pathologists 228. The clinical descriptions of rheumatic organising pneumonia have mentioned the “fleeting nature” of lung pneumonic opacities, improvement with adrenocorticotropin (ACTH), and even cited a case of “rebound phenomenon after small doses of ACTH were discontinued” 224.
Iatrogenic organising pneumonia may be drug-induced or radiation induced. Drug-induced lung disease comprises several clinical, imaging, and histological patterns including those of organising pneumonia 229, 230. Several drugs (table 3⇓) have been reported to cause iatrogenic organising pneumonia, with relatively convincing histopathological features. Causality has not been firmly established for many drugs, mainly because only isolated case reports have been published. A further difficulty results from the association of several possible causes related to the disorder for which the drug has been prescribed; for example, in patients after bone marrow graft for haematological malignancy, it is often difficult to know from among the drug(s) received, infection(s) induced by iatrogenic aplasia, and immunological and inflammatory processes associated with graft versus host disease, which of these actually caused organising pneumonia.
Organising pneumonia secondary to bleomycin treatment for malignancies may present with multiple pulmonary nodules on imaging, thus mimicking pulmonary metastases [242–246 289]. The crazy-paving pattern in bleomycin-induced organising pneumonia is uncommon 247.
A peculiar iatrogenic organising pneumonia is one that is “primed” by radiation therapy to the breast (tangential field radiotherapy) 109, 290–300. It closely resembles COP and clearly differs from radiation pneumonitis, especially because it may involve nonirradiated areas of the lung and possibly be migratory. Therefore, it differs from organising pneumonia in radiation pneumonitis limited to the radiation field 299, 301. Organising pneumonia primed by radiation therapy had an incidence of 2.5% in a series of 157 patients with breast cancer who underwent radiotherapy after breast-conservative surgery 292, and a 2.4% incidence in another series of 206 patients 300. It usually develops within 9–16 months after radiation therapy 291, 296, 301, with the mean age of affected patients being ∼60 yrs. As in COP, the patients present with fever, nonproductive cough, mild dyspnoea and peripheral alveolar opacities on chest imaging with a pattern of consolidation and further ground-glass opacities. Often initially unilateral and located in the irradiated lung, these are migratory in many patients. In BAL, a “mixed pattern” is present at differential cell count with a marked increase in lymphocytes (∼40%), and a mild increase in neutrophils (∼4–10%) and eosinophils (∼3%). Mast cells are often present (∼1–2%) 291, 293 and the CD4/CD8 ratio of lymphocytes is decreased 293. Corticosteroid treatment results in rapid clinical improvement with clearing of the pulmonary opacities on imaging without significant sequelae, in contrast with radiation pneumonitis resulting in retractile consolidation with traction bronchiectasis. However, as in COP, relapses are frequent upon reducing (to daily doses of 5–10 mg prednisone) or stopping corticosteroids, with opacities in the same or other locations. Radiation-primed organising pneumonia is thus quite similar to COP. Interestingly, this peculiar iatrogenic organising pneumonia provides some insight into the pathogenesis of COP. Patients receiving radiation therapy to the breast develop bilateral alveolar lymphocytosis of similar intensity in both lungs within 15 days after completion of radiotherapy, regardless of whether the patients later develop pneumonitis or not 303–305. This suggests that after lymphocytic alveolitis has been “primed” by radiation therapy, a second trigger or individual characteristics (either genetic or acquired) may be required for organising pneumonia to develop. Most patients receive concomitant medical treatment (especially chemotherapy and/or tamoxifen), but no definite role of the drugs used has been identified as increasing the risk of organising pneumonia. However, fever and cough developed in one patient who received radiation therapy to the breast while receiving transtuzumab, with alveolar opacities in both lungs on imaging. A biopsy of an alveolar opacity in the nonirradiated lung found a histopathological pattern of organising pneumonia 287. The patient improved once transtuzumab was discontinued without adding corticosteroids. A patient who had received radiation therapy to the breast 10 yrs earlier developed severe organising pneumonia while receiving single-agent chemotherapy with doxorubicin 260, which might correspond to the phenomenon of “radiation recall” described with doxorubicin. The latter two cases represent examples of possible triggers for radiation-primed organising pneumonia. However, more common agents, such as respiratory infections, could also play a triggering role.
Some other causes of organising pneumonia have been reported. An epidemic of organising pneumonia due to the aerosolised textile dye Acramin FWN has been reported 306–309. However, a number of patients were characterised by severe progressive disease (especially those with an infiltrative pattern on imaging) with irreversible fibrosis and ensuing death. These patients had a histopathological pattern including hyaline membranes and mural incorporation of intra-alveolar fibrosis, suggesting the organising stage of diffuse alveolar damage rather than typical organising pneumonia 306, 308. Paraquat ingestion usually results in diffuse alveolar damage, but hyaline membranes were not present in a fatal case with intra-alveolar fibrosis 310. Organising pneumonia has been reported in association with cocaine use 311, including a case of a pregnant female with HIV infection 205.
Cavitating organising pneumonia was reported in a floor cleaner with an incidental heavy exposure to benzalkonium compounds; in addition, this patient had myeloperoxidase deficiency 312. A spice process technician developed organising pneumonia of presumed occupational origin 313.
An aetiological role for gastro-oesophageal reflux with occult aspiration has been suggested in several cases 314, 315, but has not been convincingly demonstrated as a common cause of organising pneumonia when histopathological criteria of aspiration pneumonia (exogeneous lipid pneumonia with multinucleated foreign-body giant cells) are not present 175, 316. Patchy organising pneumonia is a feature of middle lobe syndrome 317.
Organising pneumonia within a specific context
Organising pneumonia may develop in patients with a well characterised disorder of unknown cause, such as connective tissue disease. It may also occur secondary to lung transplantation or bone marrow grafting. In such situations, organising pneumonia is considered as a pulmonary manifestation of the inflammatory and/or immune process associated with the underlying condition, but the synergistic role of iatrogenic or infectious agents must be systematically evaluated. The aetiology of organising pneumonia in such conditions is likely to be plurifactorial.
Connective tissue disorders may comprise lung involvement of various types, especially interstitial lung disease, which usually develops during the course of disease, but which may also precede its recognition. In clinical practice, many patients with connective tissue disease and interstitial lung disease do not undergo lung biopsy. In patients with lung biopsy, NSIP is the most common histopathological pattern associated with scleroderma, dermatomyositis–polymyositis and rheumatoid arthritis. Organising pneumonia occurs particularly in patients with dermatomyositis–polymyositis 318–331, where it may be the presenting manifestation 212, 332. In some patients it is associated with anti-JO-1 auto-antibodies 324, 326, 333. Organising pneumonia has also been reported in rheumatoid arthritis 158, 334–337, and more occasionally in systemic lupus erythematosus 338–341, scleroderma 342, 343, CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia) syndrome with primary biliary cirrhosis 15, 344, and Sjögren syndrome 345, 346. Abundant buds of organising pneumonia have been reported in association with NSIP in a patient with scleroderma 347.
In the connective tissue diseases, organising pneumonia may be the main histopathological feature, but a minor component of organising pneumonia may be associated with another histopathological pattern of interstitial pneumonia, especially NSIP. Overlap between organising pneumonia and eosinophilic pneumonia has also been reported 140, 319.
Organising pneumonia has increasingly been reported in patients after lung transplantation or bone marrow graft. The former terminology of COP (i.e. idiopathic bronchiolitis with organising pneumonia) was a source of confusion with bronchiolitis obliterans with airflow obstruction (obliterative bronchiolitis), which is the major cause of lung transplant failure and also a severe complication after allogenic bone marrow graft resulting from immune processes (namely transplant rejection and graft versus host disease, respectively). Several cases of organising pneumonia have been reported after lung transplantation 183, 200, 203, 348–351. In this context, when not explained by a determined cause (such as infection, which is common in this immunosuppressed population), organising pneumonia may be considered as an associated or predominant pattern of acute lung rejection with or without concomitant “pure” bronchiolitis obliterans 200, 183, 200, 352, 353. Furthermore, it is a risk factor for the bronchiolitis obliterans syndrome 350. Organising pneumonia has also been reported after bone marrow graft 93, 354–366, where it is strongly associated with prior acute and chronic graft versus host disease 93, 357. Some cases of organising pneumonia have also been reported after liver transplantation 367–369.
Organising pneumonia may occur in association with various haematological disorders or malignancies 90, 93 including: acute myelomonocytic leukaemia with inversion of chromosome 16 370; acute lymphoblastic leukaemia 371; chronic myelomonocytic leukaemia 372; myelodysplastic syndrome 354, 373, 374; T-cell adult leukaemia 375, 376; Evans syndrome 377; Ewing sarcoma 371; Hodgkin disease 371; and various cancers with or without radiation therapy to the chest 378. In patients with treated haematological malignancies and suspected invasive pulmonary aspergillosis, open lung biopsy may provide a diagnosis of organising pneumonia in up to ∼20% of cases 379. Organising pneumonia is frequently found in the vicinity of lung cancer 380, whether obstructive pneumonia is present or not. Obstructive pneumonia whatever its cause (e.g. foreign body inhalation) may comprise features of lipid pneumonia, chronic abscess and organising pneumonia. Coexistence of organising pneumonia with bronchioloalveolar carcinoma has been reported 381.
Although the most prevalent and distinctive pattern of respiratory involvement in inflammatory bowel disease (i.e. Crohn's disease and ulcerative colitis) is airway inflammation with ensuing bronchiectasis and/or obliterative bronchiolitis 382, organising pneumonia (focal or diffuse) is a well established manifestation of those disorders 231, 382–385. Interestingly, the mononuclear cell infiltration in the pulmonary interstitium is denser and more uniform than in COP, suggesting a possible overlap with NSIP 231. In contrast to patients with large airway disease, organising pneumonia does not manifest post-colectomy 231. Since drugs used to treat these conditions may themselves cause organising pneumonia, the issue remains complex.
Ulcerative colitis suspected to have been transmitted from donor to recipient after allogeneic bone marrow transplantation in a patient with acute myeloblastic leukaemia developed concomitantly with organising pneumonia 361.
Other disorders with associated organising pneumonia include: common variable hypogammaglobulinaemia and other immunoglobulin deficiencies 386–388; polyarteritis nodosa 389; Sweet syndrome 390–392; polymyalgia rheumatica 393, 394; Behçet disease 395; thyroid disease (including cancer, Basedow disease, thyroiditis, hypothyroidism) 396; and sarcoidosis (with organising pneumonia at the periphery of granulomatous lesions) 397. It was also reported after coronary artery bypass graft surgery 398 or in association with localised giant inflammatory polyposis of the caecum and distal ulcerative colitis 399.
SEVERE AND/OR OVERLAPPING COP
One of the main characteristics of COP is its rapid improvement with corticosteroid treatment, both clinically and on imaging. Furthermore, COP is seldom life threatening at presentation. Nevertheless, some cases atypical for these features have been reported.
COP may present with widespread opacities on imaging and hypoxaemia, corresponding to the criteria for acute lung injury or the ARDS. Although hypoxaemia with alveolar right-to-left shunt may be well tolerated as mentioned previously, other patients may require mechanical ventilation (noninvasive or with tracheal intubation) or progress to death, especially when corticosteroid treatment is delayed 400, 401. This occurs particularly in patients with delayed diagnosis who may improve once corticosteroid treatment is given (sometimes in association with immunosuppressive agents when corticosteroid resistance is suspected) 248, 402–407. In some patients, underlying conditions or exposure (connective tissue disease, drugs, infection) are associated 248, 408.
Some patients, who may have underlying conditions or exposure, present with acute fibrinous and organising pneumonia, a recently described condition overlapping with ARDS both clinically and pathologically 409. The onset is acute and progression may be fulminating or subacute. The dominant finding at lung biopsy is the presence of intra-alveolar fibrin in the form of “fibrin balls” without classic hyaline membranes. Some patients recover with treatment including corticosteroids, whereas other patients die.
This pathological pattern has also been reported upon autopsy of patients with severe acute respiratory syndrome 410 and in dermatomyositis 411. The presence of fibrin in the organising lesions at lung biopsy of patients with COP has been associated with less complete recovery under corticosteroids 412.
Overlap with acute interstitial pneumonia (idiopathic) or ARDS (when a cause is present) is likely to explain the majority of cases of severe acute organising pneumonia with poor outcome. In such cases, the organising stage of diffuse alveolar damage may overlap with the histopathological features of organising pneumonia on lung biopsy 405, 413–419.
Rare cases of progression of COP to fibrosis and honeycombing have been reported, especially in patients with the infiltrative imaging pattern of organising pneumonia, and particularly when associated histopathological and imaging features of UIP are present 138, 248, 417, 420. In some patients, acute exacerbation of idiopathic interstitial pneumonia may comprise organising pneumonia at lung biopsy 421. Superimposed organising pneumonia was found on explant specimens from a patient with UIP who underwent lung transplantation 422. Intra-alveolar organising lesions are common in the early fibrotic lesions in UIP 423. Pathological predictors of unfavourable outcome in COP include scarring and remodelling of the background lung parenchyma, suggesting that some cases might fall into a category of subacute injury in UIP 424.
All of the previous situations correspond to cases of COP that are somewhat atypical, clinically and/or histopathologically. In such an eventuality, corticosteroid treatment should be instituted, but the outcome is uncertain.
TREATMENT OF COP
Corticosteroid treatment in COP results in rapid clinical improvement and clearing of the opacities on chest imaging without significant sequelae. However, relapses are common upon stopping or reduction of corticosteroids, thus often leading to prolonged treatment. Although the efficiency of corticosteroid treatment has long been established, as is usual in such so-called orphan diseases the precise dose and duration of treatment have not been established.
Initial doses vary from ∼0.75–1.5 mg·kg-1·day-1, with further boluses of methylprednisolone on the first few days and a progressive decrease of dosage over the following weeks 89, 97, 425, 426. The duration of treatment is not established, but 1 yr is often proposed.
Relapses are common, but their reported frequency depends on several parameters including the existence of underlying conditions or exposures in the published series, and the duration of treatment. It varies from 13% 90 to 58% of cases 89. The current author's policy is to propose low doses of corticosteroids and a short duration of treatment, in order to avoid the side-effects of corticosteroids and treatment for long periods without necessity in patients who would not relapse 89. Since relapses are not associated with increased mortality nor long-term functional morbidity, most informed patients accept an increased risk of relapse rather than having high doses of corticosteroids for up to 1 yr.
In a study of relapses in COP 89, the initial dose of corticosteroid to treat the first episode was 50±17 mg. Relapses (2.4±2.2) occurred in 58% of patients, with 19% having multiple (three or more) relapses. In total, 32% of patients had stopped treatment for a mean (median) delay of 9±20 (2) months when the first relapse occurred. During the first relapse in the 68% of patients still receiving corticosteroids, the mean (median) dose was 12±7 mg, with only one (4%) patient receiving >20 mg. The predictors of relapse included delayed treatment and mildly increased gammaglutamyltransferase and alkaline phosphatase levels. A standardised treatment proposed by the Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires allowed a reduction in steroid doses; patients received 0.75 mg·kg-1 prednisone daily during 4 weeks, followed by 0.5 mg·kg-1 for 4 weeks, then 20 mg for 4 weeks, 10 mg for 6 weeks, and then 5 mg for 6 weeks before they were stopped. In severe cases, initial treatment consisted of i.v. boluses of prednisolone (2 mg·kg-1·day-1 for the first 3–5 days). Relapses while receiving prednisone at ≤20 mg daily were treated by increasing prednisone to 20 mg only, then decreasing as above. The severity of hypoxaemia as a determinant for the subsequent relapse 427 was not confirmed in the present series.
Occasional spontaneous improvement of crytogenic organising pneumonia, or response to treatment with antibiotics (especially macrolides) has been reported 16.
Fig. 1— Historical figure showing intra-alveolar buds of granulation tissue with emphasis on neoformed vessels (en). Reproduced from Tripier 8.
Fig. 2— Mechanisms of intra-alveolar organisation. a) Normal alveolus. b) Epithelial alveolar injury with necrosis of pneumocytes (especially type I pneumocytes; P1), formation of gaps in the basal lamina, and intra-alveolar leakage of coagulation plasma proteins. The balance between coagulation and fibrinolytic cascades favours coagulation and results in intra-alveolar deposits of fibrin. c) Activation, proliferation and migration of the fibroblasts (F) within the alveolar lumen through gaps in the basal lamina. d) Most fibroblasts have acquired a phenotype of myofibroblasts (MF) and produce connective matrix proteins forming mature fibrotic intra-alveolar buds composed of concentric circular layers of MF and connective matrix. CAP: capillary; P2: type 2 pneumocyte; F/M: fibroblast undergoing mitosis; C: connective matrix (collagens, fibronectin, glycoproteins).
Fig. 3— Typical cryptogenic organising pneumonia showing patchy bilateral alveolar opacities on a) chest radiograph and b) high-resolution computed tomography scan.
Fig. 4— High-resolution computed tomography showing typical cryptogenic organising pneumonia with consolidation in the left-upper lobe with an air bronchogram. Of note are two small contralateral subpleural opacities.
Fig. 5— High-resolution computed tomography of cryptogenic organising pneumonia presenting as solitary focal opacity.
Fig. 6— High-resolution computed tomography of cryptogenic organising pneumonia presenting as infiltrative lung disease.
Fig. 7— Histopathological features of organising pneumonia. a) Diffuse and prominent buds of granulation tissue represent the major histopathological pattern at low resolution. b) Typical intra-alveolar buds. c) Typical “butterfly” intra-alveolar bud. (All courtesy of L. Chalabreysse and F. Thivolet-Béjui, Dept of Pathology, Louis Pradel Hospital, Lyon, France).
Table 1— Typical distinctive characteristics of cryptogenic organising pneumonia(COP), idiopathic nonspecific interstitial pneumonia (NSIP) and idiopathic pulmonary fibrosis (IPF)
Table 2— Infectious causes of organising pneumonia
Table 3— Drugs identified as a cause of organising pneumonia
Acknowledgments
The author would to thank T. Greenland for linguistic review of the paper and M-C. Thévenet for secretarial collaboration.
- Received February 8, 2005.
- Accepted November 22, 2005.
References
- ↵
Charcot JM. Des pneumonies chroniques. Rev Mensuelle Med Chir 1878;2:776–790.
- ↵
Kidd P. Some moot points in the pathology and clinical history of pneumonia. Lancet 1912;I:1665–1670.
-
Symmers D, Hoffman AM. The increased incidence of organizing pneumonia. JAMA 1923;81:297–298.
-
Sulavik SB. The concept of “organizing pneumonia”. Chest 1989;96:967–969.
- ↵
Milne LS. Chronic pneumonia (including a discussion of two cases of syphilis of the lung). Am J Med Sci 1911;142:408–438.
- ↵
Floyd R. Organization of pneumonic exudates. Am J Med Sci 1922;163:527–548.
-
Menetrier P, Pascano A. Transformation fibreuse de l'hépatisation pneumonique ou fibrome végétant intra-alvéolaire post-pneumonique. Bull Mem Soc Med Hop Paris 1915;39:510–524.
- ↵
Tripier R. Traité d'anatomie pathologique générale. Paris, Masson, 1904
- ↵
Letulle M. Le poumon. Paris, Maloine, 1924
- ↵
Spencer H. Chronic interstitial pneumonia. In: Liebow AA, Smith DE, eds. The Lung. Baltimore, Williams & Wilkins Company, 1968; pp. 134–150
-
Galy P, Touraine R, Bailly E. A propos des scléroses pulmonaires. La pneumonie hyperplasique de Tripier-Bret et le fibrome végétant intra-alvéolaire de Ménétrier. Rev Lyonnaise Med 1954;3:45–50.
-
Gross P, Benz EJ. The concept of organizing pneumonia. Arch Pathol 1961;72:607–619.
-
Auerbach SH, Mims OM, Goodpasture EW. Pulmonary fibrosis secondary to pneumonia. Am J Pathol 1952;28:69–87.
- ↵
Scadding JG. The chronic pneumonias. Proc R Soc Med 1938;31:1259–1271.
- ↵
Davison AG, Heard BE, McAllister WAC, Turner-Warwick ME. Cryptogenic organizing pneumonitis. Q J Med 1983;52:382–394.
- ↵
Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312:152–158.
- ↵
Cordier JF, Loire R, Brune J. Idiopathic bronchiolitis obliterans organizing pneumonia. Definition of characteristic clinical profiles in a series of 16 patients. Chest 1989;96:999–1004.
- ↵
Bartter T, Irwin RS, Nash G, Balikian JP, Hollingsworth HH. Idiopathic bronchiolitis obliterans organizing pneumonia with peripheral infiltrates on chest roentgenogram. Arch Intern Med 1989;149:273–279.
- ↵
Guerry-Force ML, Muller NL, Wright JL, et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis 1987;135:705–712.
- ↵
Cordier JF, Peyrol S, Loire R. Bronchiolitis obliterans organizing pneumonia as a model of inflammatory lung disease. In: Epler GR, eds. Diseases of the bronchioles. New York, Raven Press, 1994; pp. 313–345
- ↵
Cordier JF. The concept of organizing pneumonia. In: Desmouliere A, Tuchweber B, eds. Tissue Repair and Fibrosis. The Role of the Myofibroblast. Berlin, Springer, 1999; pp. 149–156
- ↵
Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738–746.
- ↵
Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138:1257–1265.
- ↵
Peyrol S, Cordier JF, Grimaud JA. Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 1990;137:155–170.
-
Myers JL, Katzenstein AL. Ultrastructural evidence of alveolar epithelial injury in idiopathic bronchiolitis obliterans organizing pneumonia. Am J Pathol 1988;132:102–109.
- ↵
Cordier JF, Loire R, Peyrol S. Bronchiolitis obliterans organizing pneumonia (BOOP). Originalité et limites d'une entité anatomo-clinique [Bronchiolitis obliterans organizing pneumonia (BOOP). Characteristics and boundaries of an anatomo-clinical entity]. Rev Mal Respir 1991;8:139–152.
- ↵
Takiya C, Peyrol S, Cordier JF, Grimaud JA. Connective matrix organization in human pulmonary fibrosis. Collagen polymorphism analysis in fibrotic deposit by immunohistological methods. Virchows Arch 1983;44:223–240.
- ↵
Kuhn C 3rd, Boldt J, King TE, Crouch E, Vartio T, McDonald JA An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989;140:1693–1703.
- ↵
Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995;147:1759–1769.
- ↵
Specks U, Nerlich AG, Colby TV, Wiest I, Timpl R. Increased expression of type VI collagen in lung fibrosis. Am J Respir Crit Care Med 1995;151:1956–1964.
- ↵
Lappi-Blanco E, Kaarteenaho-Wiik R, Soini Y, Risteli J, Paakko P. Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized. Hum Pathol 1999;30:1192–1196.
- ↵
Lappi-Blanco E, Soini Y, Kinnula V, Paakko P. VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. J Pathol 2002;196:220–227.
- ↵
Fukuda Y, Ferrans VJ, Schoenberger CI, Rennard SI, Crystal RG. Patterns of pulmonary structural remodeling after experimental paraquat toxicity. The morphogenesis of intraalveolar fibrosis. Am J Pathol 1985;118:452–475.
- ↵
Damiano VV, Cherian PV, Frankel FR, et al. Intraluminal fibrosis induced unilaterally by lobar instillation of CdCl2 into the rat lung. Am J Pathol 1990;137:883–894.
- ↵
Rhodes GC, Lykke AW, Tapsall JW, Smith LW. Abnormal alveolar epithelial repair associated with failure of resolution in experimental streptococcal pneumonia. J Pathol 1989;159:245–253.
- ↵
Usuki J, Fukuda Y. Evolution of three patterns of intra-alveolar fibrosis produced by bleomycin in rats. Pathol Int 1995;45:552–564.
- ↵
Bellum SC, Dove D, Harley RA, et al. Respiratory reovirus 1/L induction of intraluminal fibrosis. A model for the study of bronchiolitis obliterans organizing pneumonia. Am J Pathol 1997;150:2243–2254.
- ↵
London L, Majeski EI, Paintlia MK, Harley RA, London SD. Respiratory reovirus 1/L induction of diffuse alveolar damage: a model of acute respiratory distress syndrome. Exp Mol Pathol 2002;72:24–36.
- ↵
London L, Majeski EI, Altman-Hamamdzic S, et al. Respiratory reovirus 1/L induction of diffuse alveolar damage: pulmonary fibrosis is not modulated by corticosteroids in acute respiratory distress syndrome in mice. Clin Immunol 2002;103:284–295.
- ↵
Majeski EI, Harley RA, Bellum SC, London SD, London L. Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2003;28:208–217.
- ↵
White ES, Standiford TJ. Role of polymorphonuclear leukocytes in the pathogenesis of idiopathic pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 341–357
-
Koth LL, Sheppard D. Integrins and pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 359–378
- ↵
Gharaee-Kermani M, Phan SH. Role of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 507–561
- ↵
Kunkel SL, Lukacs NW, Chensue SW, et al. Cytokines phenotypes and the progression of chronic pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 303–320
-
Strieter RM, Belperio JA, Keane MP. CXC chemokines in angiogenesis related to pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 321–339
-
Behr J. Oxidants and antioxidants in idiopathic pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 379–396
-
Peters-Golden M. Arachidonic acid metabolites: potential mediators and therapeutic targets in fibrotic lung disease. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 419–449
- ↵
Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148–157.
- ↵
Kim HJ, Bitterman PB. Peptide and provisional matrix signals in idiopathic pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 563–572
-
Rishikof DC, Ricupero DA, Goldstein RH. Extracellular matrix. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 481–506
-
Selman M, Pardo A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 451–480
- ↵
Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003;200:423–428.
- ↵
Aubert JD, Pare PD, Hogg JC, Hayashi S. Platelet-derived growth factor in bronchiolitis obliterans-organizing pneumonia. Am J Respir Crit Care Med 1997;155:676–681.
- ↵
Carre PC, King TE, Mortensesen R, Riches DWH. Cryptogenic organizing pneumonia: increased expression of interleukin-8 and fibronectin genes by alveolar macrophages. Am J Respir Cell Mol Biol 1994;10:100–105.
- ↵
Yoshinouchi T, Ohtsuki Y, Ueda R, Sato S, Ueda N. Myofibroblasts and S-100 protein positive cells in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial pneumonia. Eur Respir J 1999;14:579–584.
- ↵
Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N, Hara N. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J 2000;15:49–55.
- ↵
Kuwano K, Kawasaki M, Maeyama T, et al. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 2000;118:451–458.
- ↵
Pesci A, Majori M, Piccoli ML, et al. Mast cells in bronchiolitis obliterans organizing pneumonia. Mast cell hyperplasia and evidence for extracellular release of tryptase. Chest 1996;110:383–391.
- ↵
Forlani S, Ratta L, Bulgheroni A, et al. Cytokine profile of broncho-alveolar lavage in BOOP and UIP. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:47–53.
- ↵
Wallace WAH, Donnelly SC. Pathogenesis of acute microvascular lung injury and the acute respiratory distress syndrome. In: Evans TW, Griffiths MJD, Keogh BF, eds. ARDS. Eur Respir Mon 2002; 20:22–32.
- ↵
Bellingan GJ. Resolution of inflammation and repair. In: Evans TW, Griffiths MJD, Keogh BF, eds. ARDS Eur Respir Mon 2002;20:70–82.
- ↵
Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004
- ↵
Idell S. Fibrin turnover in pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 397–417
-
Portnoy J, Mason RJ. Role of alveolar type II epithelial cells in pulmonary fibrosis. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. New York, Marcel Dekker, 2004; pp. 573–608
-
van Valenberg PL, Lammers JW, van den Hout HA, Molema J, van Herwaarden CL. Chronic extrinsic allergic alveolitis in a family with idiopathic pulmonary fibrosis: the importance of histological diagnosis. Eur Respir J 1992;5:1154–1157.
-
Strieter RM. To clot or not to clot, that is the question in pulmonary fibrosis. Am J Respir Crit Care Med 2003;167:1589–1590.
-
Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J 2003;22: Suppl. 44 33s–5s.
- ↵
Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441–1443.
- ↵
Nesheim M. Thrombin and fibrinolysis. Chest 2003;124: Suppl. 3 33S–39S.
- ↵
Fujimoto H, Gabazza EC, Hataji O, et al. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am J Respir Crit Care Med 2003;167:1687–1694.
- ↵
Gunther A, Lubke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;168:1358–1365.
- ↵
Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448–464.
- ↵
Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000;162:1949–1956.
- ↵
Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002;121:1478–1485.
- ↵
Lappi-Blanco E, Kaarteenaho-Wiik R, Salo S, et al. Laminin-5 gamma2 chain in cryptogenic organizing pneumonia and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:27–33.
- ↵
Myers JL, Selman M. Respiratory epithelium in usual interstitial pneumonia/idiopathic pulmonary fibrosis. Spark of destructive flame? Am J Respir Crit Care Med 2004;169:3–5.
- ↵
Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500–503.
- ↵
Epperly MW, Guo H, Gretton JE, Greenberger JS. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:213–224.
-
Dunsmore SE, Shapiro SD. The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J Clin Invest 2004;113:180–182.
- ↵
Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004;113:243–252.
- ↵
Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776–1784.
- ↵
Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122: Suppl. 6 286S–289S.
- ↵
Cooper JA. Pulmonary fibrosis. Pathways are slowly coming into light. Am J Respir Cell Mol Biol 2000;22:520–523.
- ↵
Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999;177:367–376.
- ↵
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304.
- ↵
Cazzato S, Zompatori M, Baruzzi G, et al. Bronchiolitis obliterans-organizing pneumonia: an Italian experience. Respir Med 2000;94:702–708.
-
Chang J, Han J, Kim DW, et al. Bronchiolitis obliterans organizing pneumonia: clinicopathologic review of a series of 45 Korean patients including rapidly progressive form. J Korean Med Sci 2002;17:179–186.
-
Schweisfurth H, Kieslich C, Satake N, et al. Wie werden interstitielle Lungenerkrankungen in Deutschland diagnostiziert ? Ergebnisse des wissenschaftlichen Registers zur Erforschung von interstitiellen Lungenerkrankungen (“Fibroseregister”) der WATL [How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases ("Fibrosis registry") of the WATL]. Pneumologie 2003;57:373–382.
- ↵
Lazor R, Vandevenne A, Pelletier A, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med 2000;162:571–577.
- ↵
Lohr RH, Boland BJ, Douglas WW, et al. Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med 1997;157:1323–1329.
-
Katzenstein AL, Myers JL, Prophet WD, Corley LS, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol 1986;10:373–381.
-
Yamamoto M, Ina Y, Kitaichi M, Harasawa M, Tamura M. Clinical features of BOOP in Japan. Chest 1992;102: Suppl. 1 21S–25S.
- ↵
Alasaly K, Muller N, Ostrow DN, Champion P, FitzGerald JM. Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore) 1995;74:201–211.
- ↵
Dur P, Vogt P, Russi E. Bronchiolitis obliterans organizing pneumonia (BOOP)-chronic organising pneumonia (COP). Diagnosis, therapy and course. Schweiz Med Wochenschr 1993;123:1429–1438.
- ↵
Miyagawa Y, Nagata N, Shigematsu N. Clinicopathological study of migratory lung infiltrates. Thorax 1991;46:233–238.
- ↵
Costabel U, Teschler H, Schoenfeld B, et al. BOOP in Europe. Chest 1992;102: Suppl. 1 14S–20S.
- ↵
King TE, Mortenson RL. Cryptogenic organizing pneumonitis. The North American Experience. Chest 1992;102: Suppl. 1 8S–13S.
- ↵
Kelkel E, Brambilla E, Pison C, et al. La bronchiolite oblitérante avec pneumonie organisée idiopathique. Analyse anatomo-clinique et discussion nosologique. A propos de 6 observations. Ann Med Interne (Paris) 1990;141:661–667.
- ↵
Moreau L, Quoix E, Vandevenne A, et al. La bronchiolite oblitérante avec pneumopathie d'organisation. Etude rétrospective de 19 cas [Bronchiolitis obliterans with organizing pneumonia. Retrospective study of 19 cases]. Rev Pneumol Clin 1998;54:136–143.
- ↵
Boots RJ, McEvoy JD, Mowat P, Le Fevre I. Bronchiolitis obliterans organising pneumonia: a clinical and radiological review. Aust N Z J Med 1995;25:140–145.
- ↵
Chee CBE, da Costa P, Sim CS. A female with dry cough, progressive dyspnoea and weight loss. Eur Respir J 2005;25:206–209.
- ↵
Inoue T, Toyoshima K, Kikui M. Idiopathic bronchiolitis obliterans organizing pneumonia (idiopathic BOOP) in childhood. Pediatr Pulmonol 1996;22:67–72.
- ↵
Spiteri MA, Klernerman P, Sheppard MN, Padley S, Clark TJ, Newman-Taylor A. Seasonal cryptogenic organising penumonia with biochemical cholestasis: a new clinical entity. Lancet 1992;340:281–284.
- ↵
Yigla M, Ben-Itzhak O, Solomonov A, Guralnik L, Oren I. Recurrent, self-limited, menstrual-associated bronchiolitis obliterans organizing pneumonia. Chest 2000;118:253–256.
- ↵
Mroz BJ, Sexauer WP, Meade A, Balsara G. Hemoptysis as the presenting symptom in bronchiolitis obliterans organizing pneumonia. Chest 1997;111:1775–1778.
- ↵
Iwanaga T, Hirota T, Ikeda T. Air leak syndrome as one of the manifestations of bronchiolitis obliterans organizing pneumonia. Intern Med 2000;39:163–165.
- ↵
Yang DG, Kim KD, Shin DH, Choe KO, Kim SK, Lee WY. Idiopathic bronchiolitis obliterans with organizing pneumonia presenting with spontaneous hydropneumothorax and solitary pulmonary nodule. Respirology 1999;4:267–270.
- ↵
Oikonomou A, Hansell DM. Organizing pneumonia: the many morphological faces. Eur Radiol 2002;12:1486–1496.
- ↵
Flowers JR, Clunie G, Burke M, Constant O. Bronchiolitis obliterans organizing pneumonia: the clinical and radiological features of seven cases and a review of the literature. Clin Radiol 1992;45:371–377.
- ↵
Izumi T, Kitaichi M, Nishimura K, Nagai S. Bronchiolitis obliterans organizing pneumonia. Clinical features and differential diagnosis. Chest 1992;102:715–719.
-
Nishimura K, Itoh H. High-resolution computed tomographic features of bronchiolitis obliterans organizing pneumonia. Chest 1992;102: Suppl. 1 26S–31S.
-
Ackerman LV, Elliott G, Alanis M. Localized organizing pneumonia: its resemblance to carcinoma. A review of its clinical roentgenographic and pathologic features. Am J Roentgenol 1954;71:988–996.
-
Alegre-Martin J, Fernandez de Sevilla T, Garcia F, Falco V, Martinez-Vazquez JM. Three cases of idiopathic bronchiolitis obliterans with organizing pneumonia. Eur Respir J 1991;4:902–904.
- ↵
Bellomo R, Finlay M, McLaughlin P, Tai E. Clinical spectrum of cryptogenic organising pneumonitis. Thorax 1991;46:554–558.
-
Chandler PW, Shin MS, Friedman SE, Myers JL, Katzenstein AL. Radiographic manifestations of bronchiolitis obliterans with organizing pneumonia versus usual interstitial pneumonia. AJR Am J Roentgenol 1986;147:899–906.
-
Epstein DM, Bennett MR. Bronchiolitis obliterans organizing pneumonia with migratory pulmonary infiltrates. AJR Am J Roentgenol 1992;158:515–517.
-
Giron J, Parizet C, Senac JP, Durand G. La bronchiolite oblitérante avec organisation pneumonique (BOOP). A propos d'un cas et revue de la littérature [Bronchiolitis obliterans with pneumonic organization. Apropos of a case and review of the literature]. J Radiol 1991;72:95–100.
-
Louise dit Lemiere T, Carette MF, Roland J, et al. Bronchiolite oblitérante avec pneumonie organisée idiopathique. Suivi tomodensitométrique de deux cas atypiques. Rev Im Med 1991;3:729–732.
-
Meister P, Pickl-Pfeffer S, Rabben U. Bronchiolitis obliterans mit organisierender Pneumonie (“BOOP”). Fallbericht und Diskussion des Krankheitsbildes [Bronchiolitis obliterans with organized pneumonia. Case report and discussion of the disease picture]. Pathologe 1989;10:43–47.
-
Muller NL, Staples CA, Miller RR. Bronchiolitis obliterans organizing pneumonia: CT features in 14 patients. Am J Roentgenol 1990;154:983–987.
-
Muller NL, Guerry-Force ML, Staples CA, et al. Differential diagnosis of bronchiolitis obliterans with organizing pneumonia and usual interstitial pneumonia: clinical, functional, and radiologic findings. Radiology 1987;162:151–156.
-
Nishimura K, Izumi T, Kitaichi M, Nagai S, Itoh H. The diagnostic accuracy of high-resolution computed tomography in diffuse infiltrative lung diseases. Chest 1993;104:1149–1155.
-
Patel U, Jenkins PF. Bronchiolitis obliterans organizing pneumonia. Respir Med 1989;83:241–244.
-
Teschler H, Costabel U, Greschuchna D, Hartung W, Konietzeko N. Bronchiolitis obliterans mit organisierender Pneumonie. Atenw Lungenkrkh Jahrgang 1989;15:288–292.
-
Haddock JA, Hansell DM. The radiology and terminology of cryptogenic organizing pneumonia. Br J Radiol 1992;65:674–680.
-
Preidler KW, Szolar DM, Moelleken S, Tripp R, Schreyer H. Distribution pattern of computed tomography findings in patients with bronchiolitis obliterans organizing pneumonia. Invest Radiol 1996;31:251–255.
-
Voloudaki AE, Bouros DE, Froudarakis ME, Datseris GE, Apostolaki EG, Gourtsoyiannis NC. Crescentic and ring-shaped opacities. CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP). Acta Radiol 1996;37:889–892.
-
Kohno N, Ikezoe J, Johkoh T, et al. Focal organizing pneumonia: CT appearance. Radiology 1993;189:119–123.
-
Bouchardy LM, Kuhlman JE, Ball WC, Hruban RH, Askin FB, Siegelman SS. CT findings in bronchiolitis obliterans organizing pneumonia (BOOP) with radiographic, clinical, and histologic correlation. J Comput Assist Tomogr 1993;17:352–357.
-
Haro M, Vizcaya M, Texido A, Aguilar X, Arevalo M. Idiopathic bronchiolitis obliterans organizing pneumonia with multiple cavitary lung nodules. Eur Respir J 1995;8:1975–1977.
-
Froudarakis M, Bouros D, Loire R, Valasiadou K, Tsiftsis D, Siafakas NM. BOOP presenting with haemoptysis and multiple cavitary nodules. Eur Respir J 1995;8:1972–1974.
- ↵
Linsen VMJ, van Noord JA. A large air-filled cyst in a patient with migratory infiltrates. Chest 1994;105:253–254.
- ↵
Domingo JA, Perez-Calvo JI, Carretero JA, Ferrando J, Cay A, Civeira F. Bronchiolitis obliterans organizing pneumonia. An unusual cause of solitary pulmonary nodule. Chest 1993;103:1621–1623.
- ↵
Johkoh T, Muller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999;211:555–560.
- ↵
Carrington C, Addington W, Goff A, Madoff I, Marks A, Schwaber J. Chronic eosinophilic pneumonia. N Engl J Med 1969;280:787–798.
- ↵
Trisolini R, Dallari R, Cancellieri A, Poletti V. Bronchiolitis obliterans organizing pneumonia associated with lower respiratory tract infection by respiratory syncytial virus in an immunocompetent adult. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:234–235.
-
Sheehan RE, English J, Wittmann R, Muller NL. Levitating consolidation in eosinophilic lung disease. J Thorac Imaging 2003;18:45–47.
- ↵
Cordier JF. Cryptogenic organizing pneumonitis. Bronchiolitis obliterans organizing pneumonia. Clin Chest Med 1993;14:677–692.
-
Barbato A, Panizzolo C, D'Amore ES, La Rosa M, Saetta M. Bronchiolitis obliterans organizing pneumonia (BOOP) in a child with mild-to-moderate asthma: evidence of mast cell and eosinophil recruitment in lung specimens. Pediatr Pulmonol 2001;31:394–397.
- ↵
Norman D, Piecyk M, Roberts DH. Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis. Chest 2004;126:993–995.
- ↵
Hashemzadeh A, Clavel M, Musso C, Touraine F, Paraf F, Bonnaud F. Formes pseudo-néoplasiques des BOOP. Pseudoneoplastic forms of bronchiolitis obliterans with organizing pneumopathy (BOOP).]. Rev Mal Respir 2001;18:205–208.
- ↵
Wagner AL, Szabunio M, Hazlett KS, Wagner SG. Radiologic manifestations of round pneumonia in adults. Am J Roentgenol 1998;170:723–726.
-
Price J. Round pneumonia and focal organising pneumonia are different entities. Am J Roentgenol 1999;172:549
- ↵
Wagner AL. Round pneumonia focal organising pneumonia are different entities. Am J Roentgenol 1999;172:549–550.
- ↵
Yang PS, Lee KS, Han J, Kim EA, Kim TS, Choo IW. Focal organizing pneumonia: CT and pathologic findings. J Korean Med Sci 2001;16:573–578.
- ↵
Watanabe K, Harada T, Yoshida M, et al. Organizing pneumonia presenting as a solitary nodular shadow on a chest radiograph. Respiration 2003;70:507–514.
- ↵
Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False-positive FDG positron emission tomography. Uptake in nonmalignant chest abnormalities. Radiology 2004;182:983–989.
- ↵
Shin L, Katz DS, Yung E. Hypermetabolism on F-18 FDG PET of multiple pulmonary nodules resulting from bronchiolitis obliterans organizing pneumonia. Clin Nucl Med 2004;29:654–656.
- ↵
Astudillo L, Martin-Blondel G, Sans N, Dhaste G, Couret B, Arlet-Suau E. Solitary nodular form of bronchiolitis obliterans organizing pneumonia. Am J Med 2004;117:887–888.
- ↵
Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994;18:136–147.
- ↵
Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial penumonia. Am J Surg Pathol 2000;24:19–33.
- ↵
Ujita M, Renzoni EA, Veeraraghavan S, Wells AU, Hansell DM. Organizing pneumonia: perilobular pattern at thin-section CT. Radiology 2004;232:757–761.
- ↵
Orseck MJ, Player KC, Woollen CD, Kelley H, White PF. Bronchiolitis obliterans organizing pneumonia mimicking multiple pulmonary metastases. Am Surg 2000;66:11–13.
- ↵
Heller I, Biner S, Isakov A, et al. TB or not TB: cavitary bronchiolitis obliterans organizing pneumonia mimicking pulmonary tuberculosis. Chest 2001;120:674–678.
- ↵
Gaeta M, Blandino A, Scribano E, Minutoli F, Volta S, Pandolfo I. Computed tomography halo sign in pulmonary nodules: frequency and diagnostic value. J Thorac Imaging 1999;14:109–113.
- ↵
Kim SJ, Lee KS, Ryu YH, et al. Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. Am J Roentgenol 2003;180:1251–1254.
- ↵
Thivolet F, Loire R, Cordier JF. Bronchiolitis with peribronchiolar organizing pneumonia (B-POP): a new clinicopathologic entity in bronchiolar/interstitial lung disease? Eur Respir J 1999;14: Suppl. 30 272s
- ↵
Rees JH, Woodhead MA, Sheppard MN, du Bois RM. Rheumatoid arthritis and cryptogenic organising pneumonitis. Respir Med 1991;85:243–246.
- ↵
Patel AR, Shah PC, Rhee HL, Sassoon H, Rao KP. Cyclophosphamide therapy and interstitial pulmonary fibrosis. Cancer 1976;38:1542–1549.
- ↵
Naccache JM, Faure O, Loire R, Wiesendanger T, Cordier JF. Hypoxémie sévère avec orthodéoxie par shunt droit-gauche au cours d'une bronchiolite oblitérante avec organisation pneumonique idiopathique [Severe hypoxaemia with orthodeoxia due to right to left shunt in idiopathic bronchiolitis obliterans organizing pneumonia]. Rev Mal Respir 2000;17:113–116.
- ↵
Naccache JM, Wiesendanger T, Loire R, Cordier JF. Hypoxemia due to right-to-left shunt in BOOP. Eur Respir J 1999;14: Suppl. 30 228s
- ↵
Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J 1992;5:791–797.
-
Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J 1996;9:2513–2516.
- ↵
Nagai S, Aung H, Tanaka S, et al. Bronchoalveolar lavage cell findings in patients with BOOP and related diseases. Chest 1992;102: Suppl. 1 32S–37S.
- ↵
Poletti V, Castrilli G, Romagna M, et al. Bronchoalveolar lavage, histological and immunohistochemical features in cryptogenic organizing pneumonia. Monaldi Arch Chest Dis 1996;51:289–295.
- ↵
Mukae H, Kadota JI, Kohno S, Matsukura S, Hara K. Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia. Chest 1995;108:123–128.
- ↵
Colby TV. Pathologic aspects of bronchiolitis obliterans organizing pneumonia. Chest 1992;102: Suppl. 1 38S–43S.
- ↵
Kitaichi M. Differential diagnosis of bronchiolitis obliterans organizing pneumonia. Chest 1992;102: Suppl. 1 44S–49S.
- ↵
Kohn HN. Zur histologie der indurirenden fibrinösen pneumonie. Münch Med Wochenschr 1893;8:42–45.
- ↵
Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986;122:443–461.
- ↵
Mark EJ, Matsubara O, Tan-Liu NS, Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum Pathol 1988;19:1065–1071.
- ↵
Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991;15:315–333.
- ↵
Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis. A clinicopathologic study of 16 cases. Am J Surg Pathol 1996;20:794–801.
- ↵
Kawanami O, Basset F, Barrios R, Lacronique JG, Ferrans VJ, Crystal RG. Hypersensitivity pneumonitis in man. Light-and electron-microscopic studies of 18 lung biopsies. Am J Pathol 1983;110:275–289.
- ↵
Bulmer SR, Lamb D, McCormack RJ, Walbaum PR. Aetiology of unresolved pneumonia. Thorax 1978;33:307–314.
- ↵
Yousem SA, Lohr RH, Colby TV. Idiopathic bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia with unfavorable outcome: pathologic predictors. Mod Pathol 1997;10:864–871.
- ↵
Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976;7:195–204.
- ↵
Hausler M, Meilicke R, Biesterfeld S, Kentrup H, Friedrichs F, Kusenbach G. Bronchiolitis obliterans organizing pneumonia: a distinct pulmonary complication in cystic fibrosis. Respiration 2000;67:316–319.
- ↵
Fujimoto K, Muller NL, Kato S, et al. Pneumoconiosis in rush mat workers exposed to clay dye “sendo” dust. clinical, radiologic, and histopathologic features in seven patients. Chest 2004;125:737–743.
- ↵
Sison RF, Hruban RH, Moore GW, Kuhlman JE, Wheeler PS, Hutchins GM. Pulmonary disease associated with pleural “asbestos” plaques. Chest 1989;95:831–835.
- ↵
Azzam ZS, Bentur L, Rubin AH, Ben-Izhak O, Alroy G. Bronchiolitis obliterans organizing pneumonia. Diagnosis by transbronchial biopsy. Chest 1993;104:1899–1901.
- ↵
Dina R, Sheppard MN. The histological diagnosis of clinically documented cases of cryptogenic organizing pneumonia: diagnostic features in transbronchial biopsies. Histopathology 1993;23:541–545.
- ↵
Chaparro C, Chamberlain D, Maurer J, Winton T, Dehoyos A, Kesten S. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest 1996;110:1150–1154.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 48-1990. A 65-year-old man with pulmonary infiltrates after treatment for Wegener's granulomatosis. N Engl J Med 1990;323:1546–1555.
- ↵
Diehl JL, Gisselbrecht M, Meyer G, Israel-Biet D, Sors H. Bronchiolitis obliterans organizing pneumonia associated with chlamydial infection. Eur Respir J 1996;9:1320–1322.
- ↵
Janigan DR, Marrie TJ. An inflammatory pseudotumor of the lung in Q fever pneumonia. N Engl J Med 1983;308:86–88.
- ↵
Perez de Llano LA, Racamonde AV, Bande MJ, Piquer MO, Nieves FB, Feijoo AR. Bronchiolitis obliterans with organizing pneumonia associated with acute Coxiella burnetii infection. Respiration 2001;68:425–427.
- ↵
Sato P, Madtes DK, Thorning D, Albert RK. Bronchiolitis obliterans caused by Legionella pneumophila. Chest 1985;87:840–842.
- ↵
Colby TV, Myers JL. Clinical and histologic spectrum of bronchiolitis obliterans including bronchiolitis obliterans organizing pneumonia. Semin Respir Med 1992;13:119–133.
-
Chastre J, Raghu G, Soler P, Brun P, Basset F, Gibert C. Pulmonary fibrosis following pneumonia due to acute Legionnaires' disease. Clinical, ultrastructural, and immunofluorescent study. Chest 1987;91:57–62.
-
Case Records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-1978. N Engl J Med 1978;299:347–354.
-
Hernandez FJ, Kirby BD, Stanley TM, Edelstein PH. Legionnaires' disease. Post morten pathologic findings of 20 cases. Am J Clin Pathol 1980;73:488–495.
-
Winn WCJ, Myerowitz RL. The pathology of the legionella pneumonias. A review of 74 cases and the literature. Hum Pathol 1981;12:401–422.
- ↵
Ito I, Naito J, Kadowaki S, et al. Hot spring bath and Legionella pneumonia: an association confirmed by genomic identification. Intern Med 2002;41:859–863.
- ↵
Rollins S, Colby TV, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986;110:34–41.
-
Yoshinouchi T, Ohtsuki Y, Fujita J, et al. A study on intraalveolar exudates in acute Mycoplasma pneumoniae infection. Acta Med Okayama 2002;56:111–116.
- ↵
Akin J. Diagnostic dilemma. BOOP. Am J Med 2000;109:500–508.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 42-1991. A 63-year-old obese diabetic woman with a pleura-based mass in the right upper lobe. N Engl J Med 1991;325:1155–1165.
- ↵
Camp M, Mehta JB, Whitson M. Bronchiolitis obliterans and Nocardia asteroides infection of the lung. Chest 1987;92:1107–1108.
- ↵
Yousem SA, Duncan SR, Griffith BP. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol 1992;16:877–884.
- ↵
Goldstein JD, Godleski JJ, Balikian JP, Herman PG. Pathologic patterns of Serratia marcescens pneumonia. Hum Pathol 1982;13:479–484.
- ↵
Case Records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22-1973. N Engl J Med 1973;288:1173–1180.
- ↵
Abernathy EC, Hruban RH, Baumgartner WA, Reitz BA, Hutchins GM. The two forms of bronchiolitis obliterans in heart-lung transplant recipients. Hum Pathol 1991;22:1102–1110.
- ↵
Karakelides H, Aubry MC, Ryu JH. Cytomegalovirus pneumonia mimicking lung cancer in an immunocompetent host. Mayo Clin Proc 2003;78:488–490.
- ↵
Ghidini A, Mariani E, Patregnani C, Marinetti E. Bronchiolitis obliterans organizing pneumonia in pregnancy. Obstet Gynecol 1999;94:843
-
Allen JN, Wewers MD. HIV-associated bronchiolitis obliterans organizing pneumonia. Chest 1989;96:197–198.
- ↵
Sanito NJ, Morley TF, Condoluci DV. Bronchiolitis obliterans organizing pneumonia in an AIDS patient. Eur Respir J 1995;8:1021–1024.
-
Leo YS, Pitchon HE, Messler G, Meyer RD. Bronchiolitis obliterans organizing pneumonia in a patient with AIDS. Clin Infect Dis 1994;18:921–924.
-
Khater FJ, Moorman JP, Myers JW, Youngberg G, Sarubbi FA. Bronchiolitis obliterans organizing pneumonia as a manifestation of AIDS: case report and literature review. J Infect 2004;49:159–164.
- ↵
Joseph J, Harley RA, Frye MD. Bronchiolitis obliterans with organizing pneumonia in AIDS. N Engl J Med 1995;332:273
- ↵
Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001;164:847–851.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2001. Acute febrile respiratory illness in a 57-year-old man with recurrent pulmonary disorders. N Engl J Med 2001;345:1558–1565.
-
Winterbauer RH, Ludwig WR, Hammar SP. Clinical course, management, and long-term sequelae of respiratory failure due to influenza viral pneumonia. Johns Hopkins Med J 1977;141:148–155.
- ↵
Staud R, Ramos LG. Influenza A-associated bronchiolitis obliterans organizing pneumonia mimicking Wegener's granulomatosis. Rheumatol Int 2001;20:125–128.
- ↵
Peramaki E, Salmi I, Kava T, Romppanen T, Hakkarainen T. Unilateral bronchiolitis obliterans organizing pneumonia and bronchoalveolar lavage neutrophilia in a patient with parainfluenza 3 virus infection. Respir Med 1991;85:159–161.
- ↵
Ross DJ, Chan RC, Kubak B, Laks H, Nichols WS. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation. Transplant Proc 2001;33:2603–2606.
- ↵
Yale SH, Adlakha A, Sebo TJ, Ryu JH. Bronchiolitis obliterans organizing pneumonia caused by Plasmodium vivax malaria. Chest 1993;104:1294–1296.
- ↵
Flieder DB, Moran CA. Pulmonary dirofilariasis: a clinicopathologic study of 41 lesions in 39 patients. Hum Pathol 1999;30:251–256.
- ↵
Carey CF, Mueller L, Fotopoulos CL, Dall L. Bronchiolitis obliterans-organizing pneumonia associated with Cryptococcus neoformans infection. Rev Infect Dis 1991;13:1253–1254.
- ↵
Bates C, Read RC, Morice AH. A malicious mould. Lancet 1997;349:1598
- ↵
Foley NM, Griffiths MH, Miller RF. Histologically atypical Pneumocystis carinii pneumonia. Thorax 1993;48:996–1001.
- ↵
Liote H, Porte JM, Postal MJ, Martin de Lassalle E, Derenne JP. Bronchiolite oblitérante, pneumocystose et infection par le V.I.H. [Bronchiolitis obliterans, pneumocystosis and HIV infection]. Rev Mal Respir 1990;7:603–607.
- ↵
Kleindienst R, Fend F, Prior C, Margreiter R, Vogel W. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. Clin Transplant 1999;13:65–67.
- ↵
Brown G, Goldring D, Behrer MR. Rheumatic pneumonia. J Pediatr 1958;52:598–619.
- ↵
Lustok MJ, Kuzma JF. Rheumatic fever pneumonitis: a clinical and pathologic study of 35 cases. Ann Intern Med 1956;44:337–351.
-
Herbut PA, Manges WE. The “Masson body” in rheumatic pneumonia. Am J Pathol 1945;21:741–751.
- ↵
Masson P, Riopelle JL, Martin P. Poumon rhumatismal. Ann Anat Pathol 1937;14:359–382.
- ↵
Grunow WA, Esterly JR. Rheumatic pneumonitis. Chest 1972;61:298–301.
- ↵
Myers JL, Limper AH, Swensen SJ. Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances. Semin Respir Crit Care Med 2003;24:445–453.
- ↵
Ellis SJ, Cleverley JR, Muller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol 2000;175:1019–1024.
- ↵
Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993;72:151–183.
- ↵
Swinburn CR, Jackson GJ, Cobden I, Ashcroft T, Morritt GN, Corris PA. Bronchiolitis obliterans organising pneumonia in a patient with ulcerative colitis. Thorax 1988;43:735–736.
- ↵
Camus P, Lombard JN, Perrichon M, et al. Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone. Thorax 1989;44:711–715.
-
Myers JL. Diagnosis of drug reactions in the lung. Churg A, Katzenstein ALA, eds. The Lung: Current Concepts. Philadelphia, Williams and Wilkins, 1993; pp. 32–53
-
Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987;18:349–354.
-
Valle JM, Alvarez D, Antunez J, Valdes L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 1995;8:470–471.
-
Oren S, Turkot S, Golzman B, London D, Ben-Dor D, Weiler Z. Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP). Respir Med 1996;90:167–169.
-
Jessurun GA, Hoogenberg K, Crijns HJ. Bronchiolitis obliterans organizing pneumonia during low-dose amiodarone therapy. Clin Cardiol 1997;20:300–302.
-
Conte SC, Pagan V, Murer B. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: clinical, radiological and histological pattern. Monaldi Arch Chest Dis 1997;52:24–26.
- ↵
Ott MC, Khoor A, Leventhal JP, Paterick TE, Burger CD. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003;123:646–651.
- ↵
Roncoroni AJ, Corrado C, Besuschio S, Pavlovsky S, Narvaiz M. Bronchiolitis obliterans possibly associated with amphotericin B. J Infect Dis 1990;161:589
- ↵
Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia: relation to bleomycin. Chest 1985;88:103–106.
-
Zucker PK, Khouri NF, Rosenshein NB. Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity. Gynecol Oncol 1987;28:284–291.
-
Glasier CM, Siegel MJ. Multiple pulmonary nodules: unusual manifestation of bleomycin toxicity. AJR Am J Roentgenol 1981;137:155–156.
-
Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989;64:806–811.
-
Nachman JB, Baum ES, White H, Cruissi FG. Bleomycin-induced pulmonary fibrosis mimicking recurrent metastatic disease in a patient with testicular carcinoma: case report of the CT scan appearance. Cancer 1981;47:236–239.
- ↵
Rossi SE, Erasmus JJ, Volpacchio M, Franquet T, Castiglioni T, McAdams P. “Crazy-paving” pattern at thin-section CT of the lungs: radiologic-pathologic overview. Radiographics 2003;23:1509–1519.
- ↵
Cohen AJ, King TE, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994;149:1670–1675.
-
Catterall JR, McCabe RE, Brooks RG, Remington JS. Open lung biopsy in patients with Hodgkin's disease and pulmonary infiltrates. Am Rev Respir Dis 1989;139:1274–1279.
-
Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972;58:501–510.
-
O'Neill TJ, Kardinal CG, Tierney LM. Reversible interstitial pneumonitis associated with low dose bleomycin. Chest 1975;68:265–267.
- ↵
Rosenow EC, Myers JL, Swensen SJ, Pisani RJ. Drug induced pulmonary disease: an update. Chest 1992;102:239–250.
- ↵
About I, Lauque D, Levenes H, et al. Opacités alvéolaires et pneumopathies au busulfan [Broncho-alveolar lavage. From technical aspects to standards of interpretation]. Rev Mal Respir 1992;9:39–41.
- ↵
Heard BE, Cooke RA. Busulphan lung. Thorax 1968;23:187–193.
- ↵
Banka R, Ward MJ. Bronchiolitis obliterans and organising pneumonia caused by carbamazepine and mimicking community acquired pneumonia. Postgrad Med J 2002;78:621–622.
- ↵
Schmidt J, Moinard J, Milési AM, Piette JC, Aumaitre O, Marcheix JC. Pneumopathie organisée avec bronchiolite oblitérante (BOOP) et syndrome lupique induits par la carbamazépine. Rev Med Interne 1995; 16: Suppl. I, 146s
- ↵
Milesi-Lecat AM, Schmidt J, Aumaitre O, Kemeny JL, Moinard J, Piette JC. Lupus and pulmonary nodules consistent with bronchiolitis obliterans organizing pneumonia induced by carbamazepine. Mayo Clin Proc 1997;72:1145–1147.
- ↵
Dreis DF, Winterbauer RH, Van Norman GA, Sullivan SL, Hammar SP. Cephalosporin-induced interstitial pneumonitis. Chest 1984;86:138–140.
- ↵
Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, V Tsianos E. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol 2004;73:67–70.
- ↵
Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol) 2002;14:262
- ↵
Naccache JM, Kambouchner M, Girard F, et al. Relapse of respiratory insufficiency one year after organising pneumonia. Eur Respir J 2004;24:1062–1065.
- ↵
McCormick J, Cole S, Lahirir B, Knauft F, Cohen S, Yoshida T. Pneumonitis caused by gold salt therapy: evidence for the role of cell-mediated immunity in its pathogenesis. Am Rev Respir Dis 1980;122:145–152.
- ↵
Sepuya SM, Grzybowski S, Burton JD, Clement JG. Diffuse lung changes associated with gold therapy. Can Med Assoc J 1978;118:816–818.
- ↵
Doniach I, Morrison B, Steiner RE. Lung changes during hexamethonium therapy for hypertension. Br Heart J 1954;16:101–108.
- ↵
Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612–613.
- ↵
Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432–2440.
- ↵
Patel M, Ezzat W, Pauw KL, Lowsky R. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Eur J Haematol 2001;67:318–321.
- ↵
Ferriby D, Stojkovic T. Clinical picture: bronchiolitis obliterans with organising pneumonia during interferon beta-1a treatment. Lancet 2001;357:751
- ↵
Saelens T, Lamblin C, Stojkovic T, Riera-Laussel B, Wallaert B, Tonnel AB. Une pneumonie organisée secondaire à l'administration d'interféron béta 1a. Rev Mal Respir 2001;Suppl. S134
- ↵
Mar KE, Sen P, Tan K, Krishnan R, Ratkalkar K. Bronchiolitis obliterans organizing pneumonia associated with massive L-tryptophan ingestion. Chest 1993;104:1924–1926.
- ↵
Yano S, Kobayashi K, Kato K, Nishimura K. A limited form of Wegener's granulomatosis with bronchiolitis obliterans organizing pneumonitis-like variant in an ulcerative colitis patient. Intern Med 2002;41:1013–1015.
- ↵
Tanigawa K, Sugiyama K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999;66:69–72.
- ↵
Piperno D, Donné C, Loire R, Cordier JF. Bronchiolitis obliterans organizing pneumonia associated with minocycline therapy: a possible cause. Eur Respir J 1995;8:1018–1020.
- ↵
Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis: a report on eight patients. Thorax 1992;47:622–627.
- ↵
Fawcett IW, Ibrahim NB. BOOP associated with nitrofurantoin. Thorax 2001;56:161
- ↵
Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. Thorax 2000;55:249–251.
- ↵
Angle P, Thomas P, Chiu B, Freedman J. Bronchiolitis obliterans with organizing pneumonia and cold agglutinin disease associated with phenytoin hypersensitivity syndrome. Chest 1997;112:1697–1699.
- ↵
Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215–1220.
- ↵
Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transpl 2005;5:1392–1396.
- ↵
Faller M, Quoix E, Popin E, et al. Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J 1997;10:2159–2162.
- ↵
Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992;101:1033–1037.
- ↵
Ulubas B, Sahin G, Ozer C, Aydin O, Ozgur E, Apaydin D. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004;23:249–251.
- ↵
Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans and sulfasalasine therapy. Chest 1982;81:766–768.
- ↵
Gabazza EC, Taguchi O, Yamakami T, et al. Pulmonary infiltrates and skin pigmentation associated with sulfasalazine. Am J Gastroenterol 1992;87:1654–1657.
- ↵
Przepiorka D, Abu-Elmagd K, Huaringa A, et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. Bone Marrow Transplant 1993;11:502
- ↵
Alonso-Martinez JL, Elejalde-Guerra JI, Larrinaga-Linero D. Bronchiolitis obliterans-organizing pneumonia caused by ticlopidine. Ann Intern Med 1998;129:71–72.
- ↵
Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003;21:552–555.
- ↵
Bense L, Wiman LG, Steiner E, Hjerpe A. Pulmonary side effects after treatment with barbiturates. Eur J Respir Dis 1986;69:61–62.
-
Cohen MB, Austin JH, Smith-Vaniz A, Lutzky J, Grimes MM. Nodular bleomycin toxicity. Am J Clin Pathol 1989;92:101–104.
- ↵
Nambu A, Araki T, Ozawa K, Kanazawa M, Ohki Z, Miyata K. Bronchiolitis obliterans organizing pneumonia after tangential beam irradiation to the breast: discrimination from radiation pneumonitis. Radiat Med 2002;20:151–154.
- ↵
Crestani B, Valeyre D, Roden S, et al. Bronchiolitis obliterans organizing pneumonia syndrome primed by radiation therapy to the breast. Am J Respir Crit Care Med 1998;158:1929–1935.
- ↵
Takigawa N, Segawa Y, Saeki T, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys 2000;48:751–755.
- ↵
Majori M, Poletti V, Curti A, Corradi M, Falcone F, Pesci A. Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. J Allergy Clin Immunol 2000;105:239–244.
-
Bayle JY, Nesme P, Bejui-Thivolet F, Loire R, Guerin JC, Cordier JF. Migratory organizing pneumonitis “primed” by radiation therapy. Eur Respir J 1995;8:322–326.
-
Crestani B, Kambouchner M, Soler P, et al. Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma. Eur Respir J 1995;8:318–321.
- ↵
Arbetter KR, Prakash UBS, Tazelaar HD, Douglas WW. Radiation-induced pneumonitis in the “nonirradiated” lung. Mayo Clin Proc 1999;74:27–36.
-
Stover DE, Milite F, Zakowski M. A newly recognized syndrome: radiation-related bronchiolitis obliterans and organizing pneumonia. A case report and literature review. Respiration 2001;68:540–544.
-
van Laar JM, Holscher HC, Van Krieken JHJM, Stolk J. Bronchiolitis obliterans organizing pneumonia after adjuvant radiotherapy for breast carcinoma. Respir Med 1997;91:241–244.
- ↵
Kaufman J, Komorowski R. Bronchiolitis obliterans. A new clinical-pathologic complication of irradiation pneumonitis. Chest 1990;97:1243–1244.
- ↵
Miwa S, Morita S, Suda T, et al. The incidence and clinical characteristics of bronchiolitis obliterans organizing pneumonia syndrome after radiation therapy for breast cancer. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:212–218.
- ↵
Mairovitz A, Besnier M, Diot P, et al. Bronchiolite oblitérante avec pneumonie organisée: une complication de la radiothérapie [Bronchiolitis obliterans organizing pneumonia: a complication of radiotherapy]. Rev Pneumol Clin 1997;53:207–209.
-
Gil J, Barroso E, Aranda I, Fernandez C, Martin C, Romero S. Bronchiolitis obliterans organizing pneumonia. A pathologic finding with multiple causes. Am J Respir Crit Care Med 1998;157:A69
- ↵
Martin C, Romero S, Sanchez-Paya J, Massuti B, Arriero JM, Hernandez L. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J 1999;13:727–732.
-
Gibson PG, Bryant DH, Morgan GW, et al. Radiation-induced lung injury: a hypersensitivity pneumonitis? Ann Intern Med 1988;109:288–291.
- ↵
Roberts CM, Foulcher E, Zaunders JJ, et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 1993;118:696–700.
- ↵
Romero S, Hernandez L, Gil J, Aranda I, Martin C, Sanchez-Paya J. Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J 1998;11:265–271.
-
Camus P, Nemery B. A novel cause for bronchiolitis obliterans organizing pneumonia: exposure to paint aerosols in textile workshops. Eur Respir J 1998;11:259–262.
- ↵
Sole A, Cordero PJ, Morales P, Martinez ME, Vera F, Moya C. Epidemic outbreak of interstitial lung disease in aerographics textile workers - the “Ardystil syndrome”: a first year follow-up. Thorax 1996;51:94–95.
- ↵
Moya C, Anto JM, Taylor AJ. Outbreak of organizing pneumonia in textile printing sprayers. Lancet 1994;343:498–502.
- ↵
Copland GM, Kolin A, Shulman HS. Fatal pulmonary intra-alveolar fibrosis after paraquat ingestion. N Engl J Med 1974;291:290–292.
- ↵
Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med 1987;107:186–187.
- ↵
Di Stefano F, Verna N, Di Giampaolo L, Boscolo P, Di Gioacchino M. Cavitating BOOP associated with myeloperoxidase deficiency in a floor cleaner with an incidental heavy exposure to benzalkonium compounds. J Occup Health 2003;45:182–184.
- ↵
Alleman T, Darcey DJ. Case report: bronchiolitis obliterans organizing pneumonia in a spice process technician. J Occup Environ Med 2002;44:215–216.
- ↵
Sadoun D, Valeyre D, Cargill J, Volter F, Amouroux J, Battesti JP. Bronchiolite oblitérante avec pneumonie en voie d'organisation en apparence cryptogénétique. Mise en évidence d'un reflux gastro-oesophagien dans 5 cas. Presse Med 1988;17:2383–2385.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2003. A 47-year-old man with waxing and waning pulmonary nodules five years after treatment for testicular seminoma. N Engl J Med 2003;348:2019–2027.
- ↵
Katzenstein AL, Askin FB. Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 3rd Edn. Philadelphia, W.B. Saunders, 1997
- ↵
Kwon KY, Myers JL, Swensen SJ, Colby TV. Middle lobe syndrome: a clinicopathological study of 21 patients. Hum Pathol 1995;26:302–307.
- ↵
Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182–1185.
- ↵
Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999;210:333–338.
-
Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990;141:727–733.
-
Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987;14:102–107.
-
Schwarz MI, Matthay RA, Sahn SA, Stanford RE, Marmorstein BL, Scheinhorn DJ. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore) 1976;55:89–104.
-
Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614–622.
- ↵
Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyotrophic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003;22:245–250.
-
Hsue YT, Paulus HE, Coulson WF. Bronchiolitis obliterans organizing pneumonia in polymyositis. A case report with long term survival. J Rheumatol 1993;20:877–879.
- ↵
Kalenian M, Zweiman B. Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies: an interesting association. Clin Diagn Lab Immunol 1997;4:236–240.
-
Imasaki T, Yoshii A, Tanaka S, Ogura T, Ishikawa A, Takahashi T. Polymyositis and Sjogren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Intern Med 1996;35:231–235.
-
Lee YH, Choi SJ, Ji JD, et al. Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. Korean J Intern Med 2000;15:85–88.
-
Mahler DA. Dyspnea and muscle weakness in a 65 year-old woman. Chest 1992;102:1875–1876.
-
Ikezoe J, Johkoh T, Kohno N, Takeuchi N, Ichikado K, Nakamura H. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imaging 1996;11:250–259.
- ↵
Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44:585–596.
- ↵
Fata F, Rathore R, Schiff C, Herzlich BC. Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis. South Med J 1997;90:227–230.
- ↵
Chan WM, Ip M, Lau CS, Wang E, Peh WCG. Anti-Jo1 syndrome presenting as cryptogenic organizing pneumonia. Respir Med 1995;89:639–641.
- ↵
Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985;131:770–777.
-
Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004;232:81–91.
-
van Thiel RJ, van der Burg S, Groote AD, Nossent GD, Wills SH. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Eur Respir J 1991;4:905–911.
- ↵
Ippolito JA, Palmer L, Spector S, Kane PB, Gorevic PD. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 1993;23:70–78.
- ↵
Min JK, Hong YS, Park SH, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol 1997;24:2254–2257.
-
Otsuka F, Amano T, Hashimoto N, et al. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus with antiphospholipid antibody. Intern Med 1996;35:341–344.
-
Mana F, Mets T, Vincken W, Sennesael J, Vanwaeyenbergh J, Goossens A. The association of bronchiolitis obliterans organizing pneumonia, systemic lupus erythematosus, and Hunner's cystitis. Chest 1993;104:642–644.
- ↵
Gammon RB, Bridges TA, al-Nezir H, Alexander CB, Kennedy JI. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992;102:1171–1174.
- ↵
Shimizu Y, Tsukagoshi H, Nemoto T, Honma M, Nojima Y, Mori M. Recurrent bronchiolitis obliterans organizing pneumonia in a patient with limited cutaneous systemic sclerosis. Rheumatol Int 2002;22:216–218.
- ↵
Bridges AJ, Hsu KC, Dias-Arias AA, Chechani V. Bronchiolitis obliterans organizing pneumonia and scleroderma. J Rheumatol 1992;19:1136–1140.
- ↵
Davison AG, Epstein O. Relapsing organising pneumonia in a man with primary biliary cirrhosis, CREST syndrome, and chronic pancreatitis. Thorax 1983;38:316–317.
- ↵
Matteson EL, Ike RW. Bronchiolitis obliterans organizing pneumonia and Sjogren's syndrome. J Rheumatol 1990;17:676–679.
- ↵
Lambert M, Hebbar M, Viget N, Hatron PY, Hachulla E, Devulder B. Bronchiolite oblitérante avec pneumopathie organisée: une complication rare du syndrome de Gougerot-Sjögren primitif [Bronchiolitis obliterans with organized pneumonia: a rare complication of primary Gougerot-Sjogren syndrome]. Rev Med Interne 2000;21:74–77.
- ↵
Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001;60:281–283.
- ↵
Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002;21:1062–1067.
-
Milne DS, Gascoigne AD, Ashcroft T, Sviland L, Malcolm AJ, Corris PA. Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis. Transplantation 1994;57:1757–1762.
- ↵
Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297–310.
- ↵
Barberis M, Bauer D, Harari S, Belloni PA, Masini T, Baisi A. Early infections and bronchiolitis obliterans-organizing pneumonia in single lung transplant recipients. J Heart Lung Transplant 1992;11:1012–1014.
- ↵
Egan JJ, Sarker S, Hasleton PS, Woodcock AA, Yonan N, Deiraniya AK. Should cryptogenic organizing pneumonia be included in the classification of pulmonary allograft rejection? J Heart Lung Transplant 1996;15:1268–1269.
- ↵
Siddiqui MT, Garrity ER, Husain AN. Bronchiolitis obliterans organizing pneumonia-like reactions: a nonspecific response or an atypical form of rejection or infection in lung allograft recipients? Hum Pathol 1996;27:714–719.
- ↵
Brown MJ, Miller RR, Muller NL. Acute lung disease in the immunocompromised host: CT and pathologic examination findings. Radiology 1994;190:247–254.
-
Patriarca F, Skert C, Sperotto A, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004;33:1–8.
-
Evans A, Steward CG, Lyburn ID, Grier DJ. Imaging in haematopoietic stem cell transplantation. Clin Radiol 2003;58:201–214.
- ↵
Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft versus host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003;102:3822–3828.
-
Hayes-Jordan A, Benaim E, Richardson S, et al. Open lung biopsy in pediatric bone marrow transplant patients. J Pediatr Surg 2002;37:446–452.
-
Tanaka N, Matsumoto T, Miura G, Emoto T, Matsunaga N. HRCT findings of chest complications in patients with leukemia. Eur Radiol 2002;12:1512–1522.
-
Kanamori H, Mishima A, Tanaka M, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) with suspected liver graft versus host disease after allogeneic bone marrow transplantation. Transpl Int 2001;14:266–269.
- ↵
Baron FA, Hermanne JP, Dowlati A, et al. Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21:951–954.
-
Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995;26:668–675.
-
Thirman MJ, Devine SM, O'Toole K, et al. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. Bone Marrow Transplant 1992;10:307–311.
-
Mathew P, Bozeman P, Krance RA, Brenner MK, Heslop HE. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;13:221–223.
-
Kanda Y, Takahashi T, Imai Y, et al. Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1997;19:1251–1253.
- ↵
Kanamori H, Fujisawa S, Tsuburai T, et al. Increased exhaled nitric oxide in bronchiolitis obliterans organizing pneumonia after allogeneic bone marrow transplantation. Transplantation 2002;74:1356–1358.
- ↵
DeAngelo AJ, Ouellette D. Bronchiolitis obliterans organizing pneumonia in an orthotopic liver transplant patient. Transplantation 2002;73:544–546.
-
Kohli-Seth R, Killu C, Amolat MJ, et al. Bronchiolitis obliterans organizing pneumonia after orthotopic liver transplantation. Liver Transpl 2004;10:456–459.
- ↵
Hummel P, Cangiarella JF, Cohen JM, Yang G, Waisman J, Chhieng DC. Transthoracic fine-needle aspiration biopsy of pulmonary spindle cell and mesenchymal lesions: a study of 61 cases. Cancer 2001;93:187–198.
- ↵
Perez-Zincer F, Juturi JV, Hsi ED, Hoeltge GA, Rybicki LA, Kalaycio ME. A pulmonary syndrome in patients with acute myelomonocytic leukemia and inversion of chromosome 16. Leuk Lymphoma 2003;44:103–109.
- ↵
Helton KJ, Kuhn JP, Fletcher BD. Bronchiolitis obliterans-organizing pneumonia (BOOP) in children with malignant disease. Pediatr Radiol 1992;22:270–274.
- ↵
Stemmelin GR, Bernaciak J, Casas JG. Bronchiolitis with leukemia. Ann Intern Med 1991;114:912–913.
- ↵
Tenholder MF, Becker GL, Cervoni MI. The myelodysplastic syndrome and bronchiolitis obliterans. Ann Intern Med 1990;112:714–715.
- ↵
Wohlrab JL, Anderson ED, Read CA. A patient with myelodyplastic syndrome, pulmonary nodules, and worsening infiltrates. Chest 2001;120:1014–1017.
- ↵
Matsuo K, Tada S, Kataoka M, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in a case of smouldering adult T-cell leukaemia. Respirology 2000;5:81–85.
- ↵
Vaiman E, Odeh M, Attias D, Ben-Arie Y, Oliven A. T-cell chronic lymphocytic leukaemia with pulmonary involvement and relapsing BOOP. Eur Respir J 1999;14:471–474.
- ↵
Maiz L, Munoz A, Maldonado S, Pacheco A, Lamas A, Fogue L. Bronchiolitis obliterans organizing pneumonia associated with Evans syndrome. Respiration 2001;68:631–634.
- ↵
Mokhtari M, Bach PB, Tietjen PA, Stover DE. Bronchiolitis obliterans organizing pneumonia in cancer: a case series. Respir Med 2002;96:280–286.
- ↵
Kim K, Lee MH, Kim J, et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002;71:75–79.
- ↵
Romero S, Barroso E, Rodriguez-Paniagua M, Aranda FI. Organizing pneumonia adjacent to lung cancer: frequency and clinico-pathologic features. Lung Cancer 2002;35:195–201.
- ↵
Song J, Gorgan L, Corkey R, Kwa SL. An unusual case of bronchiolitis obliterans organizing pneumonia concomitant with bronchioloalveolar carcinoma. Respiration 2004;71:95–97.
- ↵
Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000;15:5–10.
-
Duracher C, Mohammedi I, Taniere P, et al. Le SDRA expression clinique inhabituelle de la bronchiolite oblitérante avec pneumonie organisée. Ann Fr Anesth Reanim 2002;21:534–537.
-
Peschard S, Akpan T, Brinkane A, Gaudin B, Leroy-Terquem E, Levy R. Bronchiolite oblitérante avec pneumonie organisée et rectocolite hémorragique. Gastroenterol Clin Biol 2000;24:848–849.
- ↵
Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003;27:213–219.
- ↵
Wislez M, Sibony M, Naccache JM, et al. Organizing pneumonia related to common variable immunodeficiency. Case report and literature review. Respiration 2000;67:467–470.
-
Popa V, Colby TV, Reich SB. Pulmonary interstitial disease in Ig deficiency. Chest 2002;122:1594–1603.
- ↵
Kaufman J, Komorowski R. Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome. Chest 1991;100:552–553.
- ↵
Robinson BW, Sterrett G. Bronchiolitis obliterans associated with polyarteritis nodosa. Chest 1992;102:309–311.
- ↵
Longo MI, Pico M, Bueno C, et al. Sweet's syndrome and bronchiolitis obliterans organizing pneumonia. Am J Med 2001;111:80–81.
-
Reid PT, Alderdice J, Carson J, Sinnamon DG. Cryptogenic organizing pneumonia in association with Sweet's syndrome. Respir Med 1996;90:57–59.
- ↵
Chien SM, Jambrosic J, Mintz S. Pulmonary manifestations in Sweet's syndrome: first report of a case with bronchiolitis obliterans organizing pneumonia. Am J Med 1991;91:553–554.
- ↵
Stey C, Truninger K, Marti D, Vogt P, Medici TC. Bronchiolitis obliterans organizing pneumonia associated with polymyalgia rheumatica. Eur Respir J 1999;13:926–929.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1986. A 65-year-old woman with bilateral pulmonary infiltrates. N Engl J Med 1986;314:1627–1635.
- ↵
Gul A, Yilmazbayhan D, Buyukbabani N, et al. Organizing pneumonia associated with pulmonary artery aneurysms in Behcet's disease. Rheumatology (Oxford) 1999;38:1285–1289.
- ↵
Watanabe K, Senju S, Maeda F, Yshida M. Four cases of bronchiolitis obliterans organizing pneumonia associated with thyroid disease. Respiration 2000;67:572–576.
- ↵
Rodriguez E, Lopez D, Buges J, Torres M. Sarcoidosis-associated bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001;161:2148–2149.
- ↵
Guzman EJ, Smith AJ, Tietjen PA. Bronchiolitis obliterans-organizing pneumonia after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2000;119:382–383.
- ↵
Koinuma K, Togashi K, Konishi F, et al. Localized giant inflammatory polyposis of the cecum associated with distal ulcerative colitis. J Gastroentrol 2003;38:880–883.
- ↵
Nizami IY, Kissner DG, Visscher DW, Dubaybo BA. Idiopathic bronchiolitis obliterans with organizing pneumonia. An acute and life-threatening syndrome. Chest 1995;108:271–277.
- ↵
Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683–693.
- ↵
Koinuma D, Miki M, Ebina M, et al. Successful treatment of a case with rapidly progressive bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med 2002;41:26–29.
-
Husain SJ, Irfan M, Zubairi AS, Salahuddin N. Rapidly-progressive bronchiolitis obliterans organising pneumonia. Singapore Med J 2004;45:283–285.
-
Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med 1997;91:175–177.
- ↵
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2003. A 73-year-old woman with pneumonia and progressive respiratory failure. N Engl J Med 2003;348:1902–1912.
-
Perez de Llano LA, Soilan JL, Garcia Pais MJ, Mata I, Moreda M, Laserna B. Idiopathic bronchiolitis obliterans with organizing pneumonia presenting with adult respiratory distress syndrome. Respir Med 1998;92:884–886.
- ↵
Schwarz MI. Diffuse pulmonary infiltrates and respiratory failure following 2 weeks of dyspnea in a 45-year-old woman. Chest 1993;104:927–929.
- ↵
Iannuzzi MC, Farhi DC, Bostrom PD, Petty TL, Fisher JH. Fulminant respiratory failure and death in a patient with idiopathic bronchiolitis obliterans. Arch Intern Med 1985;145:733–734.
- ↵
Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002;126:1064–1070.
- ↵
Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 2005;18:1–10.
- ↵
Prahalad S, Bohnsack JF, Maloney CG, Leslie KO. Fatal acute fibrinous and organizing pneumonia in a child with juvenile dermatomyositis. J Pediatr 2005;146:289–292.
- ↵
Yoshinouchi T, Ohtsuki Y, Kubo K, Shikata Y. Clinicopathological study on two types of cryptogenic organizing pneumonitis. Respir Med 1995;89:271–278.
- ↵
Bonaccorsi A, Cancellieri A, Chilosi M, et al. Acute interstitial pneumonia: report of a series. Eur Respir J 2003;21:187–191.
-
Ichikado K, Johkoh T, Ikezoe J, et al. A case of acute interstitial pneumonia indistinguishable from bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia: high-resolution CT findings and pathologic correlation. Radiat Med 1998;16:367–370.
-
Patel SR, Karmpaliotis D, Ayas NT, et al. The role of open-lung biopsy in ARDS. Chest 2004;125:197–202.
-
Tomashefski JF. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000;21:435–466.
- ↵
King Jr TE. Bronchiolitis. Schwarz MI, King Jr TE, eds. Interstitial Lung Diseases. 4th Edn. Hamilton, BC Dekker Inc, 2003; pp. 787–824
-
Kobayashi H, Itoh T, Sasaki Y, Konishi J. Diagnostic imaging of idiopathic adult respiratory distress syndrome (ARDS)/diffuse alveolar damage (DAD) histopathological correlation with radiological imaging. Clin Imaging 1996;20:1–7.
- ↵
Tse GMK, To KF, Chan PKS, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004;57:260–265.
- ↵
Wright L, King TE. Cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia): an update. Clin Pulm Med 1997;4:152–158.
- ↵
Dallari R, Foglia M, Paci M, Cavazza A. Acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2004;23:792
- ↵
Katzenstein AL, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002;26:1567–1577.
- ↵
Fukuda Y, Basset F, Ferrans VJ, Yamanaka N. Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol 1995;26:53–61.
- ↵
Yousem SA, Lohr RH, Colby TV. Idiopathic bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia with unfavorable outcome: pathologic predictors. Mod Pathol 1997;10:864–871.
- ↵
Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001;161:158–164.
- ↵
Wells AU. Cryptogenic organizing pneumonia. Semin Respir Crit Care Med 2001;22:449–459.
- ↵
Watanabe K, Senju S, Wen FQ, Shirakusa T, Maeda F, Yoshida M. Factors related to the relapse of bronchiolitis obliterans organizing pneumonia. Chest 1998;114:1599–1606.